<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002190.pub5" GROUP_ID="ARI" ID="600800032810032811" MERGED_FROM="" MODIFIED="2017-05-18 00:17:41 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A063" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2017-05-18 00:17:37 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2017-02-08 15:37:26 +1000" MODIFIED_BY="Ann Jones">Vaccines for the common cold</TITLE>
<CONTACT MODIFIED="2017-05-18 00:17:37 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="EBCE90A482E26AA20125F76B19B8D250" ROLE="AUTHOR"><FIRST_NAME>Daniel</FIRST_NAME><LAST_NAME>Simancas-Racines</LAST_NAME><POSITION>Cochrane Ecuador Coordinator</POSITION><EMAIL_1>danielsimancas10@gmail.com</EMAIL_1><EMAIL_2>dsimancas@ute.edu.ec</EMAIL_2><MOBILE_PHONE>+593992520285</MOBILE_PHONE><ADDRESS><DEPARTMENT>Cochrane Ecuador, Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><CITY>Quito</CITY><COUNTRY CODE="EC">Ecuador</COUNTRY><PHONE_1>+593992520285</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-05-18 00:17:37 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="EBCE90A482E26AA20125F76B19B8D250" ROLE="AUTHOR"><FIRST_NAME>Daniel</FIRST_NAME><LAST_NAME>Simancas-Racines</LAST_NAME><POSITION>Cochrane Ecuador Coordinator</POSITION><EMAIL_1>danielsimancas10@gmail.com</EMAIL_1><EMAIL_2>dsimancas@ute.edu.ec</EMAIL_2><MOBILE_PHONE>+593992520285</MOBILE_PHONE><ADDRESS><DEPARTMENT>Cochrane Ecuador, Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><CITY>Quito</CITY><COUNTRY CODE="EC">Ecuador</COUNTRY><PHONE_1>+593992520285</PHONE_1></ADDRESS></PERSON><PERSON ID="z1508271432074948060608761266446" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Juan</FIRST_NAME><MIDDLE_INITIALS>VA</MIDDLE_INITIALS><LAST_NAME>Franco</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>juan.franco@hospitalitaliano.org.ar</EMAIL_1><ADDRESS><DEPARTMENT>Argentine Cochrane Centre</DEPARTMENT><ORGANISATION>Instituto Universitario del Hospital Italiano</ORGANISATION><ADDRESS_1>Potosí 4234</ADDRESS_1><ADDRESS_2>Buenos Aires</ADDRESS_2><CITY>Buenos Aires</CITY><ZIP>C1199ACL</ZIP><REGION>Buenos Aires</REGION><COUNTRY CODE="AR">Argentina</COUNTRY><PHONE_1>+5491162938136</PHONE_1></ADDRESS></PERSON><PERSON ID="7AAE442982E26AA200CE028467C48372" ROLE="AUTHOR"><FIRST_NAME>Claudia</FIRST_NAME><MIDDLE_INITIALS>V</MIDDLE_INITIALS><LAST_NAME>Guerra</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Lecturer</POSITION><EMAIL_1>cguerra@ute.edu.ec</EMAIL_1><EMAIL_2>clauvero@hotmail.com</EMAIL_2><MOBILE_PHONE>+593 9810 0893</MOBILE_PHONE><ADDRESS><DEPARTMENT>Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><ADDRESS_1>Avenida Mariana de Jesús y Occidental</ADDRESS_1><CITY>Quito</CITY><ZIP>593</ZIP><REGION>Pichincha</REGION><COUNTRY CODE="EC">Ecuador</COUNTRY><PHONE_1>+593 2 299 0800</PHONE_1><FAX_1>+593 2 299 0800</FAX_1></ADDRESS></PERSON><PERSON ID="7A9ABFD282E26AA200CE0284F57654D8" ROLE="AUTHOR"><FIRST_NAME>Maria</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Felix</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Chief Neonatal Intensive Care</POSITION><EMAIL_1>mlfelix7@yahoo.com</EMAIL_1><MOBILE_PHONE>+593 9947 7706</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Neonatology</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><ADDRESS_1>Av. Mariana de Jesús y Occidental</ADDRESS_1><CITY>Quito</CITY><ZIP>593</ZIP><REGION>Pichincha</REGION><COUNTRY CODE="EC">Ecuador</COUNTRY><PHONE_1>+593 2 224 3818</PHONE_1><FAX_1>+593 2 299 0800</FAX_1></ADDRESS></PERSON><PERSON ID="08D393BD82E26AA20165205A1BB3662E" ROLE="AUTHOR"><FIRST_NAME>Ricardo</FIRST_NAME><LAST_NAME>Hidalgo</LAST_NAME><SUFFIX>PhD</SUFFIX><POSITION>Rector</POSITION><EMAIL_1>rho@ute.edu.ec</EMAIL_1><ADDRESS><DEPARTMENT>Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><ADDRESS_1>Av. Mariana de Jesús y Occidental 593</ADDRESS_1><CITY>Quito</CITY><REGION>Pichincha</REGION><COUNTRY CODE="EC">Ecuador</COUNTRY><PHONE_1>+593 2 299 0800</PHONE_1><FAX_1>+593 2 299 0800</FAX_1></ADDRESS></PERSON><PERSON ID="15772" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria José</FIRST_NAME><LAST_NAME>Martinez-Zapata</LAST_NAME><POSITION>Clinical Researcher</POSITION><EMAIL_1>mmartinezz@santpau.cat</EMAIL_1><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1><ADDRESS_2>Pavilion 18</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08025</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 93 553 78 08</PHONE_1><PHONE_2>+34 93 553 78 14</PHONE_2><FAX_1>+34 93 553 78 09</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-05-16 15:05:11 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="2" MONTH="9" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="9" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="2" MONTH="9" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="6" YEAR="2013"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2017"/>
</DATES>
<WHATS_NEW MODIFIED="2017-05-16 15:05:06 +1000" MODIFIED_BY="Liz Dooley">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2017-05-16 15:05:06 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="2" MONTH="9" YEAR="2016"/>
<DESCRIPTION>
<P>We recruited three new authors to update this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-16 15:04:58 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="2" MONTH="9" YEAR="2016"/>
<DESCRIPTION>
<P>We updated our searches and excluded three new trials (<LINK REF="STD-Glenn-2016" TYPE="STUDY">Glenn 2016</LINK>; <LINK REF="STD-Karron-2015" TYPE="STUDY">Karron 2015</LINK>; <LINK REF="STD-Kumpu-2015" TYPE="STUDY">Kumpu 2015</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2017-05-15 17:29:27 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2017-05-15 17:29:27 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>Searches conducted</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MAJOR" MODIFIED="2012-12-11 16:01:20 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Protocol taken over by a new team of review authors</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-12-11 16:01:21 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="2" YEAR="2009"/>
<DESCRIPTION>
<P>Protocol withdrawn Issue 3, 2009</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2017-03-15 09:21:13 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2017-03-15 09:21:13 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-03-15 09:20:54 +1000" MODIFIED_BY="[Empty name]">
<NAME>Universidad Tecnológica Equinoccial</NAME>
<COUNTRY CODE="EC">Ecuador</COUNTRY>
<DESCRIPTION>
<P>Methodological</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2017-03-15 09:21:13 +1000" MODIFIED_BY="[Empty name]">
<NAME>Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud Eugenio Espejo</NAME>
<COUNTRY CODE="EC">Ecuador</COUNTRY>
<DESCRIPTION>
<P>Methodological</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2017-03-15 09:18:10 +1000" MODIFIED_BY="[Empty name]">
<NAME>Instituto Universitario Hospital Italiano</NAME>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<DESCRIPTION>
<P>Methodological</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2017-01-14 00:00:53 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2017-01-14 00:00:53 +1000" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Salud Carlos III</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Mª José Martinez Zapata is funded by a Miguel Servet research contract from the Instituto de Salud Carlos III (CP15/00116).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2017-05-18 09:04:43 +1000" MODIFIED_BY="Liz  Dooley">
<SUMMARY MODIFIED="2017-05-16 13:48:21 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2017-01-22 05:03:44 +1000" MODIFIED_BY="[Empty name]">Vaccines for preventing the common cold</TITLE>
<SUMMARY_BODY MODIFIED="2017-05-16 13:48:21 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Review question</B>
</P>
<P>We looked at whether vaccines can help to prevent the common cold.</P>
<P>
<B>Background</B>
</P>
<P>The common cold is caused by viral infection of the upper respiratory tract, and people usually get better when the virus dies. People with common cold feel unwell, have runny noses, nasal congestion, sneezing, and cough with or without sore throat, and slightly elevated temperatures. Treatments are aimed at relieving symptoms.</P>
<P>Globally, the common cold causes widespread illness. It has been difficult to produce vaccines to prevent the common cold due to the many viruses involved. The effect of vaccines on preventing the common cold in healthy people is still unknown.</P>
<P>
<B>Search date</B>
</P>
<P>For this update we searched the literature up to 2 September 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We found no new studies in this update. This review includes one previously identified randomised controlled trial performed in 1965. This study involved 2307 healthy people at a training facility for the United States Navy and evaluated the effect of a live weakened (attenuated) adenovirus vaccine compared to a fake vaccine (placebo).</P>
<P>
<B>Study funding sources</B>
</P>
<P>This study was funded by a government institution.</P>
<P>
<B>Key results</B>
</P>
<P>There were no differences in the frequency of occurrence of the common cold between those who received the vaccine compared to those who received a fake vaccine. There were no adverse events related to the vaccine. However, due to the low numbers of people included in the study and numbers of colds, as well as flaws in the study design, our confidence in the results is low. Further research may be able to clarify if vaccines can prevent common cold, since the current evidence does not support the use of adenovirus vaccine to prevent common cold in healthy people.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>We assessed the quality of the evidence as low due to high risk of bias and low numbers of people included in the study and numbers of colds, which resulted in imprecision.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2017-05-16 13:48:10 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2017-05-14 14:27:15 +1000" MODIFIED_BY="[Empty name]">
<P>The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, sneezing, cough, malaise, sore throat, and fever (usually &lt; 37.8º C). The widespread morbidity caused by the common cold worldwide is related to its ubiquitousness rather than its severity. The development of vaccines for the common cold has been difficult because of antigenic variability of the common cold virus and the indistinguishable multiple other viruses and even bacteria acting as infective agents. There is uncertainty regarding the efficacy and safety of interventions for preventing the common cold in healthy people. This is an update of a Cochrane review first published in 2011 and previously updated in 2013.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-06-04 19:58:46 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2017-05-16 13:48:10 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (September 2016), MEDLINE (1948 to September 2016), Embase (1974 to September 2016), CINAHL (1981 to September 2016), and LILACS (1982 to September 2016). We also searched three trials registers for ongoing studies and four websites for additional trials (February 2017). We included no language or date restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2017-01-22 05:02:48 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) of any virus vaccines compared with placebo to prevent the common cold in healthy people.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2017-02-14 12:06:08 +1000" MODIFIED_BY="Liz Dooley">
<P>Two review authors independently evaluated methodological quality and extracted trial data. We resolved disagreements by discussion or by consulting a third review author.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2017-05-14 13:46:57 +1000" MODIFIED_BY="[Empty name]">
<P>We found no additional RCTs for inclusion in this update. This review includes one RCT dating from the 1960s with an overall high risk of bias. The RCT included 2307 healthy participants, all of whom were included in analyses. This trial compared the effect of an adenovirus vaccine against placebo. No statistically significant difference in common cold incidence was found: there were 13 (1.14%) events in 1139 participants in the vaccines group and 14 (1.19%) events in 1168 participants in the placebo group (risk ratio 0.95, 95% confidence interval 0.45 to 2.02; P = 0.90). No adverse events related to the live vaccine were reported. The quality of the evidence was low due to limitations in methodological quality and a wide 95% confidence interval.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2017-05-14 13:48:06 +1000" MODIFIED_BY="[Empty name]">
<P>This Cochrane Review was based on one study with low-quality evidence. We found no conclusive results to support the use of vaccines for preventing the common cold in healthy people compared with placebo. We identified a need for well-designed, adequately powered RCTs to investigate vaccines for the common cold in healthy people. Any future trials on medical treatments for preventing the common cold should assess a variety of virus vaccines for this condition. Outcome measures should include common cold incidence, vaccine safety, and mortality related to the vaccine.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2017-05-18 09:04:43 +1000" MODIFIED_BY="Liz  Dooley">
<BACKGROUND MODIFIED="2017-05-18 09:00:36 +1000" MODIFIED_BY="Liz  Dooley">
<P> </P>
<CONDITION MODIFIED="2017-05-18 09:00:36 +1000" MODIFIED_BY="Liz  Dooley">
<P>There are no standardised definitions for a common cold (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). The common cold is a spontaneously remitting infection of the upper respiratory tract, characterised by a runny nose, nasal congestion, and sneezing, and sometimes cough, malaise, sore throat, and fever (usually &lt; 100º F). A temperature of 100º F (37.8º C) or higher for three to four days is typically associated with influenza and other respiratory diseases (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) (<LINK REF="REF-DDCP-2010" TYPE="REFERENCE">DDCP 2010</LINK>; <LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>). While benign in nature, the common cold is the most frequent illness experienced in humans. Children experience six to 11 upper respiratory tract infections per year (<LINK REF="REF-Evans-1997" TYPE="REFERENCE">Evans 1997</LINK>; <LINK REF="REF-Leder-2003" TYPE="REFERENCE">Leder 2003</LINK>; <LINK REF="REF-Nelson-2000" TYPE="REFERENCE">Nelson 2000</LINK>), and adults experience two to four episodes per year (<LINK REF="REF-Evans-1997" TYPE="REFERENCE">Evans 1997</LINK>; <LINK REF="REF-Gr_x00fc_ber-2008" TYPE="REFERENCE">Grüber 2008</LINK>; <LINK REF="REF-Harrison-2008" TYPE="REFERENCE">Harrison 2008</LINK>). Because it causes frequent absences from school and work, the common cold has become a significant economic burden (<LINK REF="REF-Glezen-2000" TYPE="REFERENCE">Glezen 2000</LINK>; <LINK REF="REF-Hall-2001" TYPE="REFERENCE">Hall 2001</LINK>; <LINK REF="REF-Henrickson-1994" TYPE="REFERENCE">Henrickson 1994</LINK>; <LINK REF="REF-Henrickson-2003" TYPE="REFERENCE">Henrickson 2003</LINK>); the cost in the United States is estimated at more than USD 60 billion each year (<LINK REF="REF-Poland-2009" TYPE="REFERENCE">Poland 2009</LINK>). Furthermore, bacterial complications can lead to morbidity and mortality (<LINK REF="REF-Thompson-2003" TYPE="REFERENCE">Thompson 2003</LINK>; <LINK REF="REF-Wat--2004" TYPE="REFERENCE">Wat 2004</LINK>). </P>
<P>The aetiology of the common cold is diverse (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) (<LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>). Children, the elderly, and other age groups with comorbidities such as prematurity, chronic lung diseases (chronic obstructive pulmonary disease), congenital heart disease, and asthma are more prone to viral infections that cause the common cold, such as respiratory syncytial virus (RSV), rhinovirus, parainfluenza, coronavirus, and adenovirus (non-polio) (<LINK REF="REF-Edlmayr-2009" TYPE="REFERENCE">Edlmayr 2009</LINK>; <LINK REF="REF-Jackson-2008" TYPE="REFERENCE">Jackson 2008</LINK>; <LINK REF="REF-Krasinski-1985" TYPE="REFERENCE">Krasinski 1985</LINK>; <LINK REF="REF-Peltola-2008" TYPE="REFERENCE">Peltola 2008</LINK>). Human rhinovirus (HRV) is responsible for 50% to 80% of common colds and is an important cause of morbidity, reduced productivity, and inappropriate use of antibiotics and over-the-counter medications. In humans, the coronavirus (HCoV 229E) causes the common cold by infecting the upper respiratory tract. This is mainly encountered in children, and re-infection occurs in adults (<LINK REF="REF-Eriksson-2006" TYPE="REFERENCE">Eriksson 2006</LINK>). The primary factors that contribute to the spread of this disease are poor hand hygiene, overcrowding, and captive populations (schools and daycare centres) (<LINK REF="REF-Harrison-2008" TYPE="REFERENCE">Harrison 2008</LINK>). </P>
</CONDITION>
<INTERVENTION MODIFIED="2017-05-16 09:32:38 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment of the common cold is symptomatic. Studies have shown that simple preventive measures are important but may be difficult to enforce practically (<LINK REF="REF-Jefferson-2011" TYPE="REFERENCE">Jefferson 2011</LINK>). Another method of prevention could be vaccination. </P>
<P>The development of vaccines for the common cold has been challenging because of multiple aetiologies, <LINK REF="REF-Poland-2009" TYPE="REFERENCE">Poland 2009</LINK>, and antigenic variability of the common cold viruses (<LINK REF="REF-Bembridge-1998" TYPE="REFERENCE">Bembridge 1998</LINK>; <LINK REF="REF-Hussell-1998" TYPE="REFERENCE">Hussell 1998</LINK>). In the case of rhinovirus, there are over 167 different rhinoviral serotypes (<LINK REF="REF-Ren-2017" TYPE="REFERENCE">Ren 2017</LINK>). For this reason, it is difficult to create a vaccine that can give total protection. However, the future for vaccines for the common cold looks promising, considering the current knowledge of the full genomes of HRV serotypes (<LINK REF="REF-Palmemberg--2009" TYPE="REFERENCE">Palmemberg 2009</LINK>). Immune responses are triggered whenever a person is infected with the same virus but with different antigenic molecules (<LINK REF="REF-Tobin--2008" TYPE="REFERENCE">Tobin 2008</LINK>). </P>
<P>One of the most common causes of respiratory diseases are rhinoviruses. A recombinant vaccine has been reported, produced with rhinovirus-derived VP1, a surface protein that is critically involved in the infection of respiratory cells, and a non-allergenic peptide of the major grass pollen type allergen Ph1 p1 (<LINK REF="REF-Edlmayr-2009" TYPE="REFERENCE">Edlmayr 2009</LINK>).</P>
<P>Adenovirus is a commonly recognised pathogen of the upper respiratory tract and has been particularly common in captive populations (<LINK REF="REF-Binn-2007" TYPE="REFERENCE">Binn 2007</LINK>). Adenovirus serotype 4 (Ad4) and serotype 7 vaccines were used during immunisation programmes starting in 1971. Unfortunately, their interruption triggered the re-emergence of adenovirus-produced diseases in crowded locations. An example of this reappearance was documented in United States military training sites in 1999, where Ad4 accounted for 98% of all diagnoses (<LINK REF="REF-Russell--2006" TYPE="REFERENCE">Russell 2006</LINK>). </P>
<P>Epidemiological and clinical studies have revealed important changes with regard to clinical adenovirus infection, including alterations in its antigenic presentation, geographical distribution, and virulence (<LINK REF="REF-Gray--2007" TYPE="REFERENCE">Gray 2007</LINK>). Adenoviral vaccines delivered orally have been used for decades to prevent respiratory illnesses. New studies have concluded that these vaccines are safe and have brought about a good immune response in the studied populations.</P>
<P>Respiratory syncytial virus causes approximately 5% of common colds in adults (<LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>). The vaccine development for RSV has had some problems due to antigenic variability, especially in proteins F and G. People who were vaccinated with the formalin-inactivated vaccine displayed X-ray evidence of severe pneumonia and bronchiolitis due to pulmonary Arthus reaction and a process of immunopotentiation. This process was induced by a T helper (Th)-2 and Th17 T cell responses with the enrolment of T cells, neutrophils, and eosinophils causing inflammation and tissue damage (<LINK REF="REF-Rey_x002d_Jurado-2017" TYPE="REFERENCE">Rey-Jurado 2017</LINK>). Where an effective vaccine can be offered, it should be administered to children younger than six months of age, when immune systems are still immature. For this reason another approach is the development of a vaccine for maternal immunisation as it has been demonstrated that RSV-neutralising antibodies are transferred efficiently through the placenta from the pregnant woman to the newborn (<LINK REF="STD-Munoz-2003" TYPE="STUDY">Munoz 2003</LINK>). Furthermore, a phase II clinical trial has found that a recombinant F nanoparticle vaccine formulation reduces the incidence of RSV infection when compared to placebo (the incidence was 11% versus 21%, respectively) in healthy women of childbearing age (<LINK REF="STD-Glenn-2016" TYPE="STUDY">Glenn 2016</LINK>).</P>
<P>Vaccines for parainfluenza (HPIV3 cp45) are safe and immunogenic in seronegative children aged between six and 18 months (<LINK REF="STD-Belshe-2004a" TYPE="STUDY">Belshe 2004a</LINK>). The vaccine has also demonstrated less risk of transmission than others (wt HPIV3), making it possible to develop more randomised trials. Bovine parainfluenza virus vaccines are also being developed, which have been well-tolerated, effective, and immunogenic in infants (<LINK REF="STD-Belshe-2004b" TYPE="STUDY">Belshe 2004b</LINK>).  </P>
</INTERVENTION>
<THEORY MODIFIED="2017-05-15 06:24:57 +1000" MODIFIED_BY="[Empty name]">
<P>Almost all vaccines work by inducing antibodies in the serum to interfere with microbial invasion of the bloodstream, or in the mucosa, and to block adherence of pathogens to epithelial cells (<LINK REF="REF-Pichichero-2009" TYPE="REFERENCE">Pichichero 2009</LINK>). To protect the body, antibodies must be efficient, neutralising agents or have opsonisation and phagocytosis properties. Correlates of protection after vaccination are sometimes absolute quantities, but are often relative. Most infections are prevented at a particular response level, but some could occur above that level because of a large challenge dose or deficient host factors. There may be more than one correlate of protection for a disease; authors refer to these as "co-correlates". Either the effector or central memory may co-correlate with protection. Cell-mediated immunity may also operate as a correlate or co-correlate of protection against disease, rather than against infection (<LINK REF="REF-Plotkin--2008" TYPE="REFERENCE">Plotkin 2008</LINK>). Some studies suggest that vaccines that mimic natural infection and take into account the structure of pathogens seem to be effective in inducing long-term protective immunity (<LINK REF="REF-Kang-2009" TYPE="REFERENCE">Kang 2009</LINK>).  </P>
</THEORY>
<IMPORTANCE MODIFIED="2017-05-15 06:29:07 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Common cold vaccines would reduce the prevalence of this disease in more than 25 million people with upper respiratory tract infections each year (<LINK REF="REF-Gonzales-2001" TYPE="REFERENCE">Gonzales 2001</LINK>). </LI>
<LI>The common cold results in an important economic burden with over 189 million missed school days, <LINK REF="REF-Roxas-2007" TYPE="REFERENCE">Roxas 2007</LINK>, and 8 million to 20 million days of restricted activity (<LINK REF="REF-Adams-1999" TYPE="REFERENCE">Adams 1999</LINK>). </LI>
<LI>If randomised controlled trials demonstrate that there is a vaccine providing efficacy and safety to prevent the common cold, scientists could continue research in this area.</LI>
</OL>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2017-02-14 12:05:00 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the clinical effectiveness and safety of vaccines for preventing the common cold in healthy people.</P>
</OBJECTIVES>
<METHODS MODIFIED="2017-05-18 07:26:17 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2017-05-18 07:26:17 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-04-29 09:54:38 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs). We did not apply limits with respect to follow-up periods.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2017-02-08 12:47:53 +1000" MODIFIED_BY="Ann Jones">
<P>Healthy people aged between 6 months and 90 years.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2017-05-18 07:26:17 +1000" MODIFIED_BY="[Empty name]">
<P>Any vaccine that prevents the common cold, which protects against RSV, rhinovirus, parainfluenza, or adenovirus (non-polio), irrespective of dose, schedule, or administration route, versus placebo. We excluded trials on the prevention of influenza A and B because influenza and the common cold are two different diseases (<LINK REF="REF-Jefferson-2012" TYPE="REFERENCE">Jefferson 2012</LINK>). See <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> for details.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2017-05-15 06:35:14 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2017-05-15 06:34:30 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Incidence of the common cold after vaccination, regardless of the causal agent determined by laboratory or clinical examination.</LI>
<LI>Vaccine safety, i.e. adverse events ("any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment") (<LINK REF="REF-Nebeker-2004" TYPE="REFERENCE">Nebeker 2004</LINK>); and adverse drug reactions ("a response to a drug which is noxious, uninitiated and which occurs at doses normally used in men for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiologic functions") (<LINK REF="REF-Nebeker-2004" TYPE="REFERENCE">Nebeker 2004</LINK>).</LI>
<LI>Mortality related to the vaccine.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2017-05-15 06:35:14 +1000" MODIFIED_BY="[Empty name]">
<P>We did not consider secondary outcomes.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2017-05-18 07:26:14 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2017-05-18 07:26:14 +1000" MODIFIED_BY="[Empty name]">
<P>We searched the following databases up to 2 September 2016:</P>
<UL>
<LI>CENTRAL (the Cochrane Central Register of Controlled Trials), which contains the Cochrane Acute Respiratory Infections Specialised Register (CENTRAL; August 2016, Issue 8), in the Cochrane Library (searched 2 September); using the strategy in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>;</LI>
<LI>MEDLINE via Ovid (from 1948 to 2 September 2016) using the strategy in <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>;</LI>
<LI>Embase via Elsevier (from 1974 to 2 September 2016) using the strategy in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>;</LI>
<LI>CINAHL via EBSCO (from 1981 to 2 September 2016) using the strategy in <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; and</LI>
<LI>LILACS via BIREME (from 1982 to 2 September 2016) using the strategy in <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>.</LI>
</UL>
<P>We used the Cochrane Highly Sensitive Search Strategy to identify randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<A HREF="https://archie.cochrane.org/sections/documents/view?document=360904011214291378&amp;format=REVMAN#REF-Lefebvre-2011">Lefebvre 2011</A>). We adapted the search strategy to search Embase, CINAHL, and LILACS.</P>
<P>We searched the following trial registries on 2 February 2017:</P>
<UL>
<LI>ISRCTN registry (<A HREF="http://www.isrctn.com">www.isrctn.com</A>);</LI>
<LI>ClinicalTrials.gov (<A HREF="https://clinicaltrials.gov/">clinicaltrials.gov/</A>); and</LI>
<LI>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<A HREF="http://www.who.int/ictrp/search/en/">www.who.int/ictrp/search/en/</A>).</LI>
</UL>
<P>We did not restrict the results by language, dates, or publication status (published, unpublished, in press, or in progress).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2017-05-16 09:36:29 +1000" MODIFIED_BY="[Empty name]">
<P>We checked the reference lists of all relevant trials and identified reviews. We searched the following websites for trials on 2 February 2017:</P>
<OL>
<LI>US Food and Drug Administration (<A HREF="http://www.fda.gov">www.fda.gov</A>);</LI>
<LI>European Medicines Agency (<A HREF="http://www.emea.europa.eu">www.emea.europa.eu</A>);</LI>
<LI>Medicines &amp; Healthcare Products Regulatory Agency (<A HREF="http://www.mhra.gov.uk/index.htm">www.mhra.gov.uk/index.htm</A>);</LI>
<LI>Evidence in Health and Social Care (<A HREF="http://www.evidence.nhs.uk/">www.evidence.nhs.uk/</A>).</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2017-05-15 07:35:48 +1000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2017-05-15 07:04:56 +1000" MODIFIED_BY="[Empty name]">
<P>Two review authors (MJMZ, JVAF) independently screened the titles and abstracts of studies identified as a result of the search for possible inclusion in the review. We retrieved full-text reports of potentially relevant studies. Two review authors (MJMZ, JVAF) independently screened the full texts to identify studies for inclusion and identified and recorded reasons for exclusion of the ineligible studies. Any disagreements were resolved through discussion or by consulting a third review author (DSR) when needed. We identified and excluded duplicates and collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>). We imposed no language restrictions.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2017-05-15 07:12:06 +1000" MODIFIED_BY="[Empty name]">
<P>We used a data collection form for study characteristics and outcome data that we had piloted on at least one study in the review. Two review authors (DSR, CVG) extracted study characteristics from the included studies. We extracted the following study characteristics.</P>
<OL>
<LI>Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, withdrawals, and date of study.</LI>
<LI>Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, and exclusion criteria.</LI>
<LI>Interventions: intervention, comparison, concomitant medications, and excluded medications.</LI>
<LI>Outcomes: primary and secondary outcomes specified and collected, and time points reported.</LI>
<LI>Notes: funding for trial, and notable conflicts of interest of trial authors.</LI>
</OL>
<P>Two review authors (DSR, CVG) independently extracted outcome data from the included studies. We had planned to note in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table if outcome data were not reported in a usable way. We had planned to resolve disagreements by consensus or by involving a third review author (RH). One review author (DSR) transferred data into the Review Manager 5 file (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We double-checked that the data were entered correctly by comparing the data presented in the systematic review with the study report. A second review author (MJMZ) spot-checked study characteristics for accuracy against the trial report.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2017-05-15 07:16:04 +1000" MODIFIED_BY="[Empty name]">
<P>Three review authors (DSR, CVG, RH) independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreements by discussion or by involving another review author (MJMZ). We assessed the risk of bias according to the following domains.</P>
<OL>
<LI>Random sequence generation.</LI>
<LI>Allocation concealment.</LI>
<LI>Blinding of participants and personnel.</LI>
<LI>Blinding of outcome assessment.</LI>
<LI>Incomplete outcome data.</LI>
<LI>Selective outcome reporting.</LI>
<LI>Other bias.</LI>
</OL>
<P>We graded each potential source of bias as high, low, or unclear and provided quotes from the study report together with a justification for our judgement in the 'Risk of bias' table. Where necessary, we considered blinding separately for different key outcomes.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2017-05-15 07:16:33 +1000" MODIFIED_BY="[Empty name]">
<P>We calculated the risk ratio (RR) with 95% confidence intervals (CIs) for incidence of the common cold.</P>
<P>We entered outcome data for the study into a data table in Review Manager 5 to calculate the treatment effects (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We used RR for dichotomous outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2017-05-15 07:18:44 +1000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the participant. We collected and analysed a single measurement for each outcome from each participant.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2017-05-15 07:24:03 +1000" MODIFIED_BY="[Empty name]">
<P>We had planned to contact investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was identified only as an abstract). Where this was not possible, and the missing data were thought to introduce serious bias, we planned to explore the impact of including such studies in the overall assessment of results by a sensitivity analysis.</P>
<P>If numerical outcome data were missing, such as standard deviations or correlation coefficients, and could not be obtained from the authors, we planned to calculate them from other available statistics such as P values, according to the methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>However, we did not apply these approaches because this update included only one study.<BR/>
</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2017-05-15 07:23:35 +1000" MODIFIED_BY="[Empty name]">
<P>We had planned use the I² statistic to measure heterogeneity among the trials in each analysis; however, this update did not include meta-analysis. If in future updates we identify substantial heterogeneity, we will report this and explore possible causes by prespecified subgroup analysis. 
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2017-02-08 13:57:42 +1000" MODIFIED_BY="Ann Jones">
<P>We did not assess publication bias using a funnel plot because we included only one trial. For future updates, we will attempt to assess whether the review is subject to publication bias by using a funnel plot if 10 or more trials are included.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2017-05-15 07:29:05 +1000" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). For future updates, we will summarise findings using a fixed-effect model according the <I>Cochrane Handbook of Systematic Reviews for Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">GRADE and 'Summary of findings' tables</HEADING>
<P>We created a 'Summary of findings' table using the following outcomes: incidence of the common cold, vaccine safety, and mortality<I>. </I>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of the evidence as it relates to the study that contributed data (<LINK REF="REF-Atkins-2004" TYPE="REFERENCE">Atkins 2004</LINK>). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), using GRADEpro GDT software (<LINK REF="REF-GRADEpro-GDT-2014" TYPE="REFERENCE">GRADEpro GDT 2014</LINK>). We justified all decisions to down- or upgrade study quality using footnotes, and made comments to aid the reader's understanding of the review where necessary.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2017-05-15 07:31:09 +1000" MODIFIED_BY="[Empty name]">
<P>In subsequent updates of this review, when sufficient data are available, we plan to carry out the following subgroup analyses:<BR/>
</P>
<OL>
<LI>children and adults;</LI>
<LI>country of study; and</LI>
<LI>different responses in relation to different viral agents.</LI>
</OL>
<P>We will explore sources of heterogeneity in the assessment of the primary outcome measure by subgroup analyses and meta-regression analyses. The meta-regression analyses will assess the effect of methodological quality (high versus low), type of virus vaccines, and participant characteristics. We will only conduct meta-regression if 10 or more RCTs are included.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2017-05-15 07:35:48 +1000" MODIFIED_BY="[Empty name]">
<P>For future updates, we plan to conduct sensitivity analyses comparing the results using all trials as follows.</P>
<OL>
<LI>Trials with high methodological quality (studies classified as having a 'low risk of bias' versus those identified as having a 'high risk of bias') (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>Trials that performed intention-to-treat versus per-protocol analyses.</LI>
</OL>
<P>We will also evaluate the risk of attrition bias, as estimated by the percentage of participants lost. We will exclude trials with a total attrition of more than 30% or where differences between the groups exceeded 10%, or both, from meta-analysis, but will include them in the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2017-05-18 09:04:43 +1000" MODIFIED_BY="Liz  Dooley">
<STUDY_DESCRIPTION MODIFIED="2017-05-15 07:42:51 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2017-05-15 07:39:22 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2016 update we assessed 221 results from our electronic searches (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded 218 records based on assessment of title and abstract. We obtained three full-text reports, which we excluded after full-text assessment. Consequently, we did not include any new studies for this update. Only one study was included (<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK>).<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2017-05-15 07:41:17 +1000" MODIFIED_BY="[Empty name]">
<P>This review included one RCT involving 2307 healthy people (<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK>). See the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2017-05-15 07:42:51 +1000" MODIFIED_BY="[Empty name]">
<P>In the previous review we excluded 41 studies (<LINK REF="STD-Belshe-1982" TYPE="STUDY">Belshe 1982</LINK>; <LINK REF="STD-Belshe-1992" TYPE="STUDY">Belshe 1992</LINK>; <LINK REF="STD-Belshe-2004a" TYPE="STUDY">Belshe 2004a</LINK>; <LINK REF="STD-Belshe-2004b" TYPE="STUDY">Belshe 2004b</LINK>; <LINK REF="STD-Clements-1991" TYPE="STUDY">Clements 1991</LINK>; <LINK REF="STD-DeVincenzo-2010" TYPE="STUDY">DeVincenzo 2010</LINK>; <LINK REF="STD-Doggett-1963" TYPE="STUDY">Doggett 1963</LINK>; <LINK REF="STD-Dudding-1972" TYPE="STUDY">Dudding 1972</LINK>; <LINK REF="STD-Falsey-1996" TYPE="STUDY">Falsey 1996</LINK>; <LINK REF="STD-Falsey-2008" TYPE="STUDY">Falsey 2008</LINK>; <LINK REF="STD-Fulginiti-1969" TYPE="STUDY">Fulginiti 1969</LINK>; <LINK REF="STD-Gomez-2009" TYPE="STUDY">Gomez 2009</LINK>; <LINK REF="STD-Gonzalez-2000" TYPE="STUDY">Gonzalez 2000</LINK>; <LINK REF="STD-Greenberg-2005" TYPE="STUDY">Greenberg 2005</LINK>; <LINK REF="STD-Hamory-1975" TYPE="STUDY">Hamory 1975</LINK>; <LINK REF="STD-Karron-1995a" TYPE="STUDY">Karron 1995a</LINK>; <LINK REF="STD-Karron-1995b" TYPE="STUDY">Karron 1995b</LINK>; <LINK REF="STD-Karron-1997" TYPE="STUDY">Karron 1997</LINK>; <LINK REF="STD-Karron-2003" TYPE="STUDY">Karron 2003</LINK>; <LINK REF="STD-Karron-2005" TYPE="STUDY">Karron 2005</LINK>; <LINK REF="STD-Langley-2009" TYPE="STUDY">Langley 2009</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Lee-2004" TYPE="STUDY">Lee 2004</LINK>; <LINK REF="STD-Lin-2007" TYPE="STUDY">Lin 2007</LINK>; <LINK REF="STD-Lyons-2008" TYPE="STUDY">Lyons 2008</LINK>; <LINK REF="STD-Madhi-2006" TYPE="STUDY">Madhi 2006</LINK>; <LINK REF="STD-Munoz-2003" TYPE="STUDY">Munoz 2003</LINK>; <LINK REF="STD-Murphy-1994" TYPE="STUDY">Murphy 1994</LINK>; <LINK REF="STD-Paradiso-1994" TYPE="STUDY">Paradiso 1994</LINK>; <LINK REF="STD-Piedra-1995" TYPE="STUDY">Piedra 1995</LINK>; <LINK REF="STD-Pierce-1968" TYPE="STUDY">Pierce 1968</LINK>; <LINK REF="STD-Power-2001" TYPE="STUDY">Power 2001</LINK>; <LINK REF="STD-Ritchie-1958" TYPE="STUDY">Ritchie 1958</LINK>; <LINK REF="STD-Simoes-2001" TYPE="STUDY">Simoes 2001</LINK>; <LINK REF="STD-Tang-2008" TYPE="STUDY">Tang 2008</LINK>; <LINK REF="STD-Top-1971" TYPE="STUDY">Top 1971</LINK>; <LINK REF="STD-Tristram-1993" TYPE="STUDY">Tristram 1993</LINK>; <LINK REF="STD-Watt-1990" TYPE="STUDY">Watt 1990</LINK>; <LINK REF="STD-Welliver-1994" TYPE="STUDY">Welliver 1994</LINK>; <LINK REF="STD-Wilson-1960" TYPE="STUDY">Wilson 1960</LINK>; <LINK REF="STD-Wright-1976" TYPE="STUDY">Wright 1976</LINK>). In this update, we excluded three new studies: two did not evaluate the common cold as an outcome (<LINK REF="STD-Glenn-2016" TYPE="STUDY">Glenn 2016</LINK>; <LINK REF="STD-Karron-2015" TYPE="STUDY">Karron 2015</LINK>), and the third study involved an intervention that was not relevant to this review (probiotics) (<LINK REF="STD-Kumpu-2015" TYPE="STUDY">Kumpu 2015</LINK>).</P>
<P>See the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2017-05-18 09:04:43 +1000" MODIFIED_BY="Liz  Dooley">
<P>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> had overall low methodological quality. See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2017-05-15 07:49:09 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed <LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> as at unclear risk of bias for random sequence generation and allocation concealment since the information provided was inadequate for judgement of this domain.</P>
</ALLOCATION>
<BLINDING MODIFIED="2017-05-18 09:04:43 +1000" MODIFIED_BY="Liz  Dooley">
<P>We assessed <LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> as at low risk of bias for blinding of participants and personnel, but unclear for outcome assessor. Although a placebo was used, there could be a risk of detection bias because common cold does not require hospitalisation.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2017-05-15 07:51:44 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed <LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> as at unclear risk of attrition bias because the information provided was insufficient to enable assessment of this domain.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2017-05-15 07:52:49 +1000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> was at high risk of bias for selective reporting. The study protocol was not available, but it was clear that the published reports include all expected outcomes. However, some of the outcomes were described in a narrative fashion and did not specify incidence for each group.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2017-05-17 19:21:48 +1000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> had a high risk for other sources of bias. Participants' base characteristics were not described, and because there was no detailed information relating to assessment of selection bias, information was insufficient to evaluate if both groups were comparable. </P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2017-05-15 08:01:49 +1000" MODIFIED_BY="[Empty name]">
<P>Results were based on one RCT (<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK>, N = 2307 healthy people), which we assessed as providing low-quality evidence. See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Incidence of the common cold</HEADING>
<P>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> (2307 participants, 27 events) showed that adenovirus vaccine was associated with a non-statistically significant reduction in the incidence of the common cold compared with placebo (RR 0.95, 95% CI 0.45 to 2.02; P = 0.90; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). We downgraded the quality of the evidence to low due to high risk of bias and imprecision; there were few events in each group, resulting in imprecision represented by a wide 95% confidence interval.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Vaccine safety</HEADING>
<P>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> reported that there were no adverse events related to the live vaccine preparation. We downgraded the quality of the evidence to low due to high risk of bias and imprecision (0 events).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Mortality related to vaccine</HEADING>
<P>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> did not assess this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2017-05-16 09:47:58 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2017-05-15 08:04:43 +1000" MODIFIED_BY="[Empty name]">
<P>We included one RCT that met our inclusion criteria. Critical appraisal of <LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> did not support the use of any virus vaccines for preventing the common cold in healthy people. We did not find significant differences in the incidence of the common cold in people treated with adenovirus vaccines compared with placebo. <LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> did not evaluate main clinical outcomes such as mortality related to the vaccine. This RCT reported that there were no adverse events related to the vaccine. The relative effect of any of the vaccines for viruses that cause the common cold remains unclear.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2017-05-16 09:47:58 +1000" MODIFIED_BY="[Empty name]">
<P>The included trial did not detect statistically significant differences between the treatment groups (<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK>).</P>
<P>When dealing with such neutral results, we need to keep in mind that 'absence of evidence' is not 'evidence of absence' (<LINK REF="REF-Altman-1995" TYPE="REFERENCE">Altman 1995</LINK>; <LINK REF="REF-Fermi-Paradox-2012" TYPE="REFERENCE">Fermi Paradox 2012</LINK>). The fact that this review did not detect any differences between the intervention groups does not imply that placebo and adenovirus vaccine have the same effect on preventing the common cold. The first possible explanation is failure to determine an appropriate sample size (<LINK REF="REF-Green-2002" TYPE="REFERENCE">Green 2002</LINK>; <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>), in this case resulting in small differences in the incidence of the common cold and few events in the comparison groups. In a remarkable paper from 28 years ago, <LINK REF="REF-Freiman-1978" TYPE="REFERENCE">Freiman 1978</LINK> suggested that "many of the therapies labelled as 'no different from control' in trials using inadequate samples, have not received a fair test" and that "concern for the probability of missing an important therapeutic improvement because of small sample sizes deserves more attention in the planning of clinical trials". <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK> emphasised that "most trials with negative results did not have large enough sample sizes to detect a 25% or a 50% relative difference". Moreover, it has been suggested that the most important therapies adopted in clinical practice have shown more modest benefits (<LINK REF="REF-Kirby-2002" TYPE="REFERENCE">Kirby 2002</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2017-05-15 08:11:59 +1000" MODIFIED_BY="[Empty name]">
<P>The results for the primary outcomes 'incidence of the common cold' and 'vaccine safety' were based on low-quality evidence due to imprecision (low number of events and wide confidence intervals) and methodological limitations. The random sequence generation, allocation, sample size, and base characteristics of participants were not reported. Furthermore, the study may be at high risk of detection bias, since the common cold syndrome rarely requires hospitalisation, and the effect of the intervention could not be adequately evaluated. The report of adverse events was not individualised for each group.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2017-05-15 08:13:34 +1000" MODIFIED_BY="[Empty name]">
<P>In the process of performing a systematic review, there is a group of biases known as 'significance-chasing' (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). This group includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, we did an exhaustive search that included many RCTs that did not evaluate common cold outcomes.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2017-05-15 08:16:11 +1000" MODIFIED_BY="[Empty name]">
<P>We found no other reviews or studies that investigated vaccines for the common cold. We excluded 11 non-RCTs that evaluated vaccines for upper respiratory tract infections (<LINK REF="STD-Belshe-1982" TYPE="STUDY">Belshe 1982</LINK>; <LINK REF="STD-Clements-1991" TYPE="STUDY">Clements 1991</LINK>; <LINK REF="STD-Doggett-1963" TYPE="STUDY">Doggett 1963</LINK>; <LINK REF="STD-Dudding-1972" TYPE="STUDY">Dudding 1972</LINK>; <LINK REF="STD-Fulginiti-1969" TYPE="STUDY">Fulginiti 1969</LINK>; <LINK REF="STD-Hamory-1975" TYPE="STUDY">Hamory 1975</LINK>; <LINK REF="STD-Karron-1997" TYPE="STUDY">Karron 1997</LINK>; <LINK REF="STD-Ritchie-1958" TYPE="STUDY">Ritchie 1958</LINK>; <LINK REF="STD-Watt-1990" TYPE="STUDY">Watt 1990</LINK>; <LINK REF="STD-Wilson-1960" TYPE="STUDY">Wilson 1960</LINK>; <LINK REF="STD-Wright-1976" TYPE="STUDY">Wright 1976</LINK>). However, only one study evaluated the incidence of common cold (<LINK REF="STD-Ritchie-1958" TYPE="STUDY">Ritchie 1958</LINK>), while the others focused on immunologic outcomes. <LINK REF="STD-Ritchie-1958" TYPE="STUDY">Ritchie 1958</LINK> prepared an "autologous vaccine" developed from the nasal secretions of 125 healthy volunteers, who were then inoculated with this product, while 75 served as a control. The results showed a lower incidence of common cold in the vaccine group than in the control group.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2017-05-15 14:04:19 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2017-05-15 14:02:56 +1000" MODIFIED_BY="[Empty name]">
<P>This Cochrane Review update found very limited evidence on the effects of vaccines for the common cold in healthy people. We included only one randomised controlled trial, which did not report differences between comparison groups. Review findings were based on only one trial assessed as providing low-quality evidence at high risk of bias and with imprecise estimates. <LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK> involved 2307 participants and assessed adenovirus vaccine compared with placebo.</P>
<P>We found insufficient evidence to support the use of vaccines for the common cold. Prescription of virus vaccines for preventing the common cold in healthy people can neither be supported nor rejected, unless new evidence from large, high-quality trials alters this conclusion. This Cochrane Review does not provide evidence about other virus vaccines for preventing the common cold in healthy people.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2017-05-15 14:04:19 +1000" MODIFIED_BY="[Empty name]">
<P>This Cochrane Review update highlights the need for well-designed, high-quality randomised trials to assess the effectiveness and safety of virus vaccines to prevent the common cold in healthy people. Future trials should include outcomes such as common cold incidence, vaccine safety, mortality related to the vaccine, and adverse events related to vaccine administration. Future trials should be conducted by independent researchers and reported according to CONSORT guidelines (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>; <LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>), and using the Foundation of Patient-Centered Outcomes Research recommendations (<LINK REF="REF-Anonymous-2012" TYPE="REFERENCE">Anonymous 2012</LINK>; <LINK REF="REF-Gabriel-2012" TYPE="REFERENCE">Gabriel 2012</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2017-05-15 14:07:09 +1000" MODIFIED_BY="[Empty name]">
<P>The authors wish to thank Tom Jefferson and David Tyrell, who coauthored the first published version of this review; Anne Lyddiatt, Gulam Khandaker, Lisa Jackson, Mark Griffin, and Meenu Singh for commenting on the draft protocol; and Theresa Wrangham, John Jordan, Viviana Rodriguez, and Meenu Singh for commenting on the first draft review.<BR/>
<BR/>The authors wish to express their thanks to Liz Dooley, Managing Editor of the Cochrane Acute Respiratory Infections Group, for her comments, which improved the quality of this review.</P>
<P>Daniel Simancas-Racines is a PhD candidate at the Department of Pediatrics, Gynecology and Obstetrics, and Preventive Medicine, Universitat Autònoma de Barcelona, Spain.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2017-04-11 14:08:03 +1000" MODIFIED_BY="Liz Dooley">
<P>Daniel Simancas-Racines: None known.<BR/>Juan VA Franco: None known.<BR/>Claudia V Guerra: None known.<BR/>Maria L Felix: None known.<BR/>Ricardo Hidalgo: None known.<BR/>Maria José Martinez-Zapata: None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2017-05-16 09:06:44 +1000" MODIFIED_BY="Liz Dooley">
<UL>
<LI>Conceiving the review: DSR</LI>
<LI>Designing the review: DSR, CVG, MLF, RH</LI>
<LI>Co-ordinating the review: DSR</LI>
<LI>Data collection for the review: DSR</LI>
<LI>Screening search results: JVAF, MJMZ</LI>
<LI>Appraising quality of papers: DSR, CVG, RH, JVAF, MJMZ</LI>
<LI>Extracting data from papers: DSR</LI>
<LI>Writing to authors of papers for additional information: DSR</LI>
<LI>Obtaining and screening data on unpublished studies: JVAF, MJMZ</LI>
<LI>Data management for the review: DSR</LI>
<LI>Entering data into Review Manager 5: DSR, JVAF, MJMZ</LI>
<LI>Interpretation of data: All authors</LI>
<LI>Providing a methodological perspective: MJMZ</LI>
<LI>Providing a clinical perspective: CVG, MLF, RH</LI>
<LI>Writing the review: DSR, JVAF, MJMZ</LI>
<LI>All authors contributed to the improvement of this updated review and approved the final version of the review.</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2017-05-16 13:46:33 +1000" MODIFIED_BY="[Empty name]">
<P>Three new authors contributed to this update: Juan VA Franco, Maria L Felix, and Maria José Martinez-Zapata.</P>
<P>We considered risk of bias as unclear for blinding in the previous version of this review. For this update, we reassessed this as low because the study used a placebo.</P>
<P>We added two additional primary outcomes, vaccine safety and mortality related to the vaccine, to <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>We did not search Scirus for this update since this service became unavailable in 2014.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2011-01-14 11:51:53 +1000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-05-18 00:17:41 +0100" MODIFIED_BY="Liz Dooley">
<STUDIES MODIFIED="2017-05-15 14:57:14 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-10-22 10:44:30 +1000" MODIFIED_BY="Clare Dooley">
<STUDY DATA_SOURCE="PUB" ID="STD-Griffin-1970" MODIFIED="2012-10-22 10:44:30 +1000" MODIFIED_BY="[Empty name]" NAME="Griffin 1970" YEAR="1970">
<REFERENCE MODIFIED="2012-06-20 03:02:41 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffin JP, Greenberg BH</AU>
<TI>Live and inactivated adenovirus vaccines. Clinical evaluation of efficacy in prevention of acute respiratory disease</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1970</YR>
<VL>125</VL>
<NO>6</NO>
<PG>981-6</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:50:59 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222027"/><IDENTIFIER TYPE="PUBMED" VALUE="4378136"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222026"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2017-05-15 14:57:14 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Belshe-1982" MODIFIED="2012-12-11 16:04:48 +1000" MODIFIED_BY="[Empty name]" NAME="Belshe 1982" YEAR="1982">
<REFERENCE MODIFIED="2012-12-11 16:04:48 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belshe RB, Van Voris LP, Mufson MA</AU>
<TI>Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1982</YR>
<VL>145</VL>
<NO>3</NO>
<PG>311-9</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:46:32 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222029"/><IDENTIFIER TYPE="PUBMED" VALUE="7037983"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222028"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belshe-1992" MODIFIED="2017-02-08 08:27:08 +1000" MODIFIED_BY="Ann Jones" NAME="Belshe 1992" YEAR="1992">
<REFERENCE MODIFIED="2017-02-08 08:27:08 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belshe RB, Karron RA, Newman FK, Anderson EL, Nugent SL, Steinhoff M, et al</AU>
<TI>Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>8</NO>
<PG>2064-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222031"/><IDENTIFIER TYPE="PUBMED" VALUE="1323576"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222030"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belshe-2004a" MODIFIED="2017-02-08 08:26:58 +1000" MODIFIED_BY="Ann Jones" NAME="Belshe 2004a" YEAR="2004">
<REFERENCE MODIFIED="2017-02-08 08:26:58 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, et al</AU>
<TI>Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>190</VL>
<NO>12</NO>
<PG>2096-103</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222033"/><IDENTIFIER TYPE="PUBMED" VALUE="15551207"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222032"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belshe-2004b" MODIFIED="2017-02-08 08:27:21 +1000" MODIFIED_BY="Ann Jones" NAME="Belshe 2004b" YEAR="2004">
<REFERENCE MODIFIED="2017-02-08 08:27:21 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, et al</AU>
<TI>Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>189</VL>
<NO>3</NO>
<PG>462-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222035"/><IDENTIFIER TYPE="PUBMED" VALUE="14745704"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222034"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clements-1991" MODIFIED="2017-02-08 08:27:31 +1000" MODIFIED_BY="Ann Jones" NAME="Clements 1991" YEAR="1991">
<REFERENCE MODIFIED="2017-02-08 08:27:31 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clements ML, Belshe RB, King J, Newman F, Westblom TU, Tierney EL, et al</AU>
<TI>Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1991</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1175-82</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:10:19 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222037"/><IDENTIFIER TYPE="PUBMED" VALUE="1650789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222036"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DeVincenzo-2010" MODIFIED="2017-02-08 08:27:44 +1000" MODIFIED_BY="Ann Jones" NAME="DeVincenzo 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-02-08 08:27:44 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, et al</AU>
<TI>A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>2010</YR>
<VL>107</VL>
<NO>19</NO>
<PG>8800-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222039"/><IDENTIFIER TYPE="PUBMED" VALUE="20421463"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222038"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doggett-1963" MODIFIED="2012-11-08 01:47:18 +1000" MODIFIED_BY="[Empty name]" NAME="Doggett 1963" YEAR="1963">
<REFERENCE MODIFIED="2012-11-08 01:46:54 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doggett JE, Bynoe ML, Tyrrell DA</AU>
<TI>Some attempts to produce an experimental vaccine with rhinoviruses</TI>
<SO>British Medical Journal</SO>
<YR>1963</YR>
<VL>1</VL>
<NO>5322</NO>
<PG>34-6</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:10:43 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222041"/><IDENTIFIER TYPE="PUBMED" VALUE="14028369"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222040"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dudding-1972" MODIFIED="2012-11-06 14:44:48 +1000" MODIFIED_BY="[Empty name]" NAME="Dudding 1972" YEAR="1972">
<REFERENCE MODIFIED="2012-06-20 03:24:46 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dudding BA, Bartelloni PJ, Scott RM, Top FH Jr, Russell PK, Buescher EL</AU>
<TI>Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers</TI>
<SO>Infection and Immunity</SO>
<YR>1972</YR>
<VL>5</VL>
<NO>3</NO>
<PG>295-9</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:11:23 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222043"/><IDENTIFIER TYPE="PUBMED" VALUE="4564559"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222042"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falsey-1996" MODIFIED="2012-10-20 12:31:39 +1000" MODIFIED_BY="[Empty name]" NAME="Falsey 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-10-20 12:31:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falsey AR, Walsh EE</AU>
<TI>Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60</TI>
<SO>Vaccine</SO>
<YR>1996</YR>
<VL>14</VL>
<NO>13</NO>
<PG>1214-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222045"/><IDENTIFIER TYPE="PUBMED" VALUE="8961507"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222044"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falsey-2008" MODIFIED="2017-05-15 14:57:14 +1000" MODIFIED_BY="[Empty name]" NAME="Falsey 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-05-15 14:57:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, et al</AU>
<TI>Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines - nonadjuvanted vaccine or vaccine adjuvanted with alum - given concomitantly with influenza vaccine to high-risk elderly individuals</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2008</YR>
<VL>198</VL>
<NO>9</NO>
<PG>1317-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222047"/><IDENTIFIER TYPE="PUBMED" VALUE="18855558"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222046"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fulginiti-1969" MODIFIED="2012-11-06 14:44:54 +1000" MODIFIED_BY="[Empty name]" NAME="Fulginiti 1969" YEAR="1969">
<REFERENCE MODIFIED="2012-06-20 03:25:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G</AU>
<TI>Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1969</YR>
<VL>89</VL>
<NO>4</NO>
<PG>435-48</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:12:06 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222049"/><IDENTIFIER TYPE="PUBMED" VALUE="4305199"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222048"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glenn-2016" MODIFIED="2017-02-08 08:30:53 +1000" MODIFIED_BY="Ann Jones" NAME="Glenn 2016" YEAR="">
<REFERENCE MODIFIED="2017-02-08 08:30:53 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="OTHER">
<AU>Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, et al</AU>
<TI>A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2016</YR>
<VL>213</VL>
<NO>3</NO>
<PG>411-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5648469"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5648468"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gomez-2009" MODIFIED="2017-01-12 23:08:57 +1000" MODIFIED_BY="[Empty name]" NAME="Gomez 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-12-11 16:10:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G</AU>
<TI>Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>655-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222051"/><IDENTIFIER TYPE="PUBMED" VALUE="19483659"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2017-01-12 23:08:57 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-01-12 23:08:57 +1000" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222050"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez-2000" MODIFIED="2017-02-08 08:31:37 +1000" MODIFIED_BY="Ann Jones" NAME="Gonzalez 2000" YEAR="2000">
<REFERENCE MODIFIED="2017-02-08 08:31:37 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, et al</AU>
<TI>Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults</TI>
<SO>Vaccine</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>17</NO>
<PG>1763-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222053"/><IDENTIFIER TYPE="PUBMED" VALUE="10699324"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222052"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-2005" MODIFIED="2017-02-08 08:31:51 +1000" MODIFIED_BY="Ann Jones" NAME="Greenberg 2005" YEAR="2005">
<REFERENCE MODIFIED="2017-02-08 08:31:51 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, et al</AU>
<TI>A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>191</VL>
<NO>7</NO>
<PG>1116-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222055"/><IDENTIFIER TYPE="PUBMED" VALUE="15747247"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222054"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamory-1975" MODIFIED="2012-12-11 16:10:53 +1000" MODIFIED_BY="[Empty name]" NAME="Hamory 1975" YEAR="1975">
<REFERENCE MODIFIED="2012-12-11 16:10:53 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamory BH, Hamparian VV, Conant RM, Gwaltney JM Jr</AU>
<TI>Human responses to two decavalent rhinovirus vaccines</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1975</YR>
<VL>132</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:12:36 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222057"/><IDENTIFIER TYPE="PUBMED" VALUE="172561"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222056"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karron-1995a" MODIFIED="2017-02-08 08:32:09 +1000" MODIFIED_BY="Ann Jones" NAME="Karron 1995a" YEAR="1995">
<REFERENCE MODIFIED="2017-02-08 08:32:09 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, et al</AU>
<TI>A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>171</VL>
<NO>5</NO>
<PG>1107-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222059"/><IDENTIFIER TYPE="PUBMED" VALUE="7751684"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karron-1995b" MODIFIED="2017-02-08 08:32:29 +1000" MODIFIED_BY="Ann Jones" NAME="Karron 1995b" YEAR="1995">
<REFERENCE MODIFIED="2017-02-08 08:32:29 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, et al</AU>
<TI>A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>172</VL>
<NO>6</NO>
<PG>1445-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222061"/><IDENTIFIER TYPE="PUBMED" VALUE="7594701"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222060"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karron-1997" MODIFIED="2017-02-08 08:32:43 +1000" MODIFIED_BY="Ann Jones" NAME="Karron 1997" YEAR="1997">
<REFERENCE MODIFIED="2017-02-08 08:32:43 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karron RA, Wright PF, Crowe JE Jr, Clements-Mann ML, Thompson J, Makhene M, et al</AU>
<TI>Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1997</YR>
<VL>176</VL>
<NO>6</NO>
<PG>1428-36</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:13:15 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222063"/><IDENTIFIER TYPE="PUBMED" VALUE="9395351"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222062"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karron-2003" MODIFIED="2017-02-08 08:32:54 +1000" MODIFIED_BY="Ann Jones" NAME="Karron 2003" YEAR="2003">
<REFERENCE MODIFIED="2017-02-08 08:32:54 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, et al</AU>
<TI>A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>5</NO>
<PG>394-405</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222065"/><IDENTIFIER TYPE="PUBMED" VALUE="12792378"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222064"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karron-2005" MODIFIED="2017-02-08 08:33:09 +1000" MODIFIED_BY="Ann Jones" NAME="Karron 2005" YEAR="2005">
<REFERENCE MODIFIED="2017-02-08 08:33:09 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, et al</AU>
<TI>Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2005</YR>
<VL>191</VL>
<NO>7</NO>
<PG>1093-104</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222067"/><IDENTIFIER TYPE="PUBMED" VALUE="15747245"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karron-2015" MODIFIED="2017-02-08 08:35:00 +1000" MODIFIED_BY="Ann Jones" NAME="Karron 2015" YEAR="">
<REFERENCE MODIFIED="2017-02-08 08:35:00 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="OTHER">
<AU>Karron RA, Mateo JS, Thumar B, Schaap-Nutt A, Buchholz UJ, Schmidt AC, et al</AU>
<TI>Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children</TI>
<SO>Journal of Pediatric Infectious Diseases Society</SO>
<YR>2015</YR>
<VL>4</VL>
<NO>4</NO>
<PG>e143-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5648471"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5648470"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumpu-2015" MODIFIED="2017-02-08 08:36:18 +1000" MODIFIED_BY="Ann Jones" NAME="Kumpu 2015" YEAR="">
<REFERENCE MODIFIED="2017-02-08 08:36:18 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="OTHER">
<AU>Kumpu M, Kekkonen RA, Korpela R, Tynkkynen S, Järvenpää S, Kautiainen H, et al</AU>
<TI>Effect of live and inactivated Lactobacillus rhamnosus GG on experimentally induced rhinovirus colds: randomised, double blind, placebo-controlled pilot trial</TI>
<SO>Beneficial Microbes</SO>
<YR>2015</YR>
<VL>6</VL>
<NO>5</NO>
<PG>631-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="5648473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="5648472"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langley-2009" MODIFIED="2017-02-08 08:37:25 +1000" MODIFIED_BY="Ann Jones" NAME="Langley 2009" YEAR="2009">
<REFERENCE MODIFIED="2017-02-08 08:37:25 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, et al</AU>
<TI>A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults &gt; or = 65 years of age</TI>
<SO>Vaccine</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>42</NO>
<PG>5913-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222069"/><IDENTIFIER TYPE="PUBMED" VALUE="19651171"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222068"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2001" MODIFIED="2017-02-08 08:37:49 +1000" MODIFIED_BY="Ann Jones" NAME="Lee 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-08 08:37:49 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, et al</AU>
<TI>Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>184</VL>
<NO>7</NO>
<PG>909-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222071"/><IDENTIFIER TYPE="PUBMED" VALUE="11509996"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2004" MODIFIED="2012-11-06 14:45:35 +1000" MODIFIED_BY="[Empty name]" NAME="Lee 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-06-20 03:26:15 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ</AU>
<TI>Experimental infection of humans with A2 respiratory syncytial virus</TI>
<SO>Antiviral Research</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>3</NO>
<PG>191-6</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:41:13 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222073"/><IDENTIFIER TYPE="PUBMED" VALUE="15451187"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222072"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2007" MODIFIED="2017-02-08 08:38:09 +1000" MODIFIED_BY="Ann Jones" NAME="Lin 2007" YEAR="2007">
<REFERENCE MODIFIED="2017-02-08 08:38:09 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin JT, Zhang JS, Su N, Xu JG, Wang N, Chen JT, et al</AU>
<TI>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</TI>
<SO>Antiviral Therapy</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>7</NO>
<PG>1107-13</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:52:55 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222075"/><IDENTIFIER TYPE="PUBMED" VALUE="18018769"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyons-2008" MODIFIED="2017-02-08 08:38:18 +1000" MODIFIED_BY="Ann Jones" NAME="Lyons 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-02-08 08:38:18 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lyons A, Longfield J, Kuschner R, Straight T, Binn L, Seriwatana J, et al</AU>
<TI>A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>23</NO>
<PG>2890-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222077"/><IDENTIFIER TYPE="PUBMED" VALUE="18448211"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madhi-2006" MODIFIED="2017-02-08 08:38:31 +1000" MODIFIED_BY="Ann Jones" NAME="Madhi 2006" YEAR="2006">
<REFERENCE MODIFIED="2017-02-08 08:38:31 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, et al</AU>
<TI>Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>13</NO>
<PG>2432-9</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:53:35 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222079"/><IDENTIFIER TYPE="PUBMED" VALUE="16406170"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munoz-2003" MODIFIED="2012-11-06 14:45:54 +1000" MODIFIED_BY="[Empty name]" NAME="Munoz 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-06-15 03:54:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munoz FM, Piedra PA, Glezen WP</AU>
<TI>Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women</TI>
<SO>Vaccine</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>24</NO>
<PG>3465-7</PG>
<IDENTIFIERS MODIFIED="2012-06-15 03:54:21 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222081"/><IDENTIFIER TYPE="PUBMED" VALUE="12850361"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1994" MODIFIED="2017-02-08 08:38:46 +1000" MODIFIED_BY="Ann Jones" NAME="Murphy 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-02-08 08:38:46 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy BR, Hall SL, Kulkarni AB, Crowe JE Jr, Collins PL, Connors M, et al</AU>
<TI>An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines</TI>
<SO>Virus Research</SO>
<YR>1994</YR>
<VL>32</VL>
<NO>1</NO>
<PG>13-36</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:41:53 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222083"/><IDENTIFIER TYPE="PUBMED" VALUE="8030364"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paradiso-1994" MODIFIED="2017-02-08 08:38:55 +1000" MODIFIED_BY="Ann Jones" NAME="Paradiso 1994" YEAR="1994">
<REFERENCE MODIFIED="2017-02-08 08:38:55 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, et al</AU>
<TI>Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>9</NO>
<PG>792-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222085"/><IDENTIFIER TYPE="PUBMED" VALUE="7808848"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piedra-1995" MODIFIED="2017-02-08 08:39:07 +1000" MODIFIED_BY="Ann Jones" NAME="Piedra 1995" YEAR="1995">
<REFERENCE MODIFIED="2017-02-08 08:39:07 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piedra PA, Glezen WP, Kasel JA, Welliver RC, Jewel AM, Rayford Y, et al</AU>
<TI>Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection</TI>
<SO>Vaccine</SO>
<YR>1995</YR>
<VL>13</VL>
<NO>12</NO>
<PG>1095-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222087"/><IDENTIFIER TYPE="PUBMED" VALUE="7491817"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pierce-1968" MODIFIED="2012-11-06 14:47:51 +1000" MODIFIED_BY="[Empty name]" NAME="Pierce 1968" YEAR="1968">
<REFERENCE MODIFIED="2012-10-20 12:33:10 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pierce WE, Rosenbaum MJ, Edwards EA, Peckinpaugh RO, Jackson GG</AU>
<TI>Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1968</YR>
<VL>87</VL>
<NO>1</NO>
<PG>237-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222089"/><IDENTIFIER TYPE="PUBMED" VALUE="4295428"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Power-2001" MODIFIED="2017-02-08 08:39:23 +1000" MODIFIED_BY="Ann Jones" NAME="Power 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-02-08 08:39:23 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, et al</AU>
<TI>Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2001</YR>
<VL>184</VL>
<NO>11</NO>
<PG>1456-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222091"/><IDENTIFIER TYPE="PUBMED" VALUE="11709789"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222090"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-1958" MODIFIED="2012-11-08 01:48:32 +1000" MODIFIED_BY="[Empty name]" NAME="Ritchie 1958" YEAR="1958">
<REFERENCE MODIFIED="2012-11-08 01:48:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie JM</AU>
<TI>Autogenous vaccine in prophylaxis of the common cold</TI>
<SO>Lancet</SO>
<YR>1958</YR>
<VL>1</VL>
<NO>7021</NO>
<PG>615-8</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:42:13 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222093"/><IDENTIFIER TYPE="PUBMED" VALUE="13515297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simoes-2001" MODIFIED="2012-11-06 14:47:58 +1000" MODIFIED_BY="[Empty name]" NAME="Simoes 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-10-20 12:33:19 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE</AU>
<TI>Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines</TI>
<SO>Vaccine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>5-6</NO>
<PG>954-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222095"/><IDENTIFIER TYPE="PUBMED" VALUE="11738763"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2008" MODIFIED="2017-02-08 08:39:42 +1000" MODIFIED_BY="Ann Jones" NAME="Tang 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-02-08 08:39:42 +1000" MODIFIED_BY="Ann Jones" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang RS, Spaete RR, Thompson MW, MacPhail M, Guzzetta JM, Ryan PC, et al</AU>
<TI>Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>50</NO>
<PG>6373-82</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:44:46 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222097"/><IDENTIFIER TYPE="PUBMED" VALUE="18822334"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Top-1971" MODIFIED="2012-12-11 16:15:42 +1000" MODIFIED_BY="[Empty name]" NAME="Top 1971" YEAR="1971">
<REFERENCE MODIFIED="2012-12-11 16:15:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Top FH Jr, Buescher EL, Bancroft WH, Russell PK</AU>
<TI>Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1971</YR>
<VL>124</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222099"/><IDENTIFIER TYPE="PUBMED" VALUE="4330998"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tristram-1993" MODIFIED="2012-12-11 16:15:50 +1000" MODIFIED_BY="[Empty name]" NAME="Tristram 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-12-11 16:15:50 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P</AU>
<TI>Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1993</YR>
<VL>167</VL>
<NO>1</NO>
<PG>191-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222101"/><IDENTIFIER TYPE="PUBMED" VALUE="8418166"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222100"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watt-1990" MODIFIED="2012-11-06 14:48:10 +1000" MODIFIED_BY="[Empty name]" NAME="Watt 1990" YEAR="1990">
<REFERENCE MODIFIED="2012-06-20 02:45:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watt PJ, Robinson BS, Pringle CR, Tyrrell DA</AU>
<TI>Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines</TI>
<SO>Vaccine</SO>
<YR>1990</YR>
<VL>8</VL>
<NO>3</NO>
<PG>231-6</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:45:24 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222103"/><IDENTIFIER TYPE="PUBMED" VALUE="2363300"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welliver-1994" MODIFIED="2012-12-11 16:16:02 +1000" MODIFIED_BY="[Empty name]" NAME="Welliver 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-12-11 16:16:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S</AU>
<TI>Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>2</NO>
<PG>425-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222105"/><IDENTIFIER TYPE="PUBMED" VALUE="8035030"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222104"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1960" MODIFIED="2012-11-08 01:50:36 +1000" MODIFIED_BY="[Empty name]" NAME="Wilson 1960" YEAR="1960">
<REFERENCE MODIFIED="2012-11-08 01:50:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson JS, Grant PJ, Miller DL, Taylor CE, McDonald JC</AU>
<TI>Trial of adenovirus vaccine in Royal Air Force recruits</TI>
<SO>British Medical Journal</SO>
<YR>1960</YR>
<VL>1</VL>
<NO>5179</NO>
<PG>1081-3</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:45:57 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222107"/><IDENTIFIER TYPE="PUBMED" VALUE="13845090"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wright-1976" MODIFIED="2012-12-11 16:16:18 +1000" MODIFIED_BY="[Empty name]" NAME="Wright 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-12-11 16:16:18 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright PF, Shinozaki T, Fleet W, Sell SH, Thompson J, Karzon DT</AU>
<TI>Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1976</YR>
<VL>88</VL>
<NO>6</NO>
<PG>931-6</PG>
<IDENTIFIERS MODIFIED="2012-06-20 02:46:15 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3222109"/><IDENTIFIER TYPE="PUBMED" VALUE="178852"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3222108"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-02-26 17:32:55 +1000" MODIFIED_BY="Clare Dooley"/>
<ONGOING_STUDIES MODIFIED="2010-03-12 10:31:33 +1000" MODIFIED_BY="Clare Dooley"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2017-05-18 09:07:33 +1000" MODIFIED_BY="Liz  Dooley">
<ADDITIONAL_REFERENCES MODIFIED="2017-05-18 09:07:33 +1000" MODIFIED_BY="Liz  Dooley">
<REFERENCE ID="REF-Abbas-2001" MODIFIED="2017-02-08 08:42:26 +1000" MODIFIED_BY="Ann Jones" NAME="Abbas 2001" TYPE="BOOK_SECTION">
<AU>Abbas A, Lichtman A</AU>
<TI>Glossary</TI>
<SO>Basic Immunology</SO>
<YR>2001</YR>
<VL>1</VL>
<PB>WB Saunders Company</PB>
<CY>Philadelphia, PA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adams-1999" MODIFIED="2010-09-24 00:06:15 +1000" MODIFIED_BY="[Empty name]" NAME="Adams 1999" TYPE="JOURNAL_ARTICLE">
<AU>Adams PF, Hendershot GE, Marano MA</AU>
<TI>Current estimates from the National Health Interview Survey 1996</TI>
<SO>Vital Health Statistics</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>200</NO>
<PG>1-203</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:06:15 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-24 00:06:15 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15782448"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Altman-1995" MODIFIED="2017-02-14 12:10:39 +1000" MODIFIED_BY="Liz Dooley" NAME="Altman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<NO>7003</NO>
<PG>485</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:11:22 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="7647644"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2012" MODIFIED="2017-05-18 07:24:47 +1000" MODIFIED_BY="[Empty name]" NAME="Anonymous 2012" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>307</VL>
<NO>15</NO>
<PG>1636-40</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:38:44 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="22511692"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arruda-1997" MODIFIED="2010-09-24 00:06:32 +1000" MODIFIED_BY="[Empty name]" NAME="Arruda 1997" TYPE="JOURNAL_ARTICLE">
<AU>Arruda E, Pitkäranta A, Witek TJ Jr, Doyle CA, Hayden FG</AU>
<TI>Frequency and natural history of rhinovirus infections in adults during autumn</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1997</YR>
<VL>35</VL>
<NO>11</NO>
<PG>2864-8</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:06:32 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-24 00:06:32 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9350748"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Atkins-2004" MODIFIED="2017-02-08 14:02:47 +1000" MODIFIED_BY="Ann Jones" NAME="Atkins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al; GRADE Working Group</AU>
<TI>Grading quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7454</NO>
<PG>1490</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bembridge-1998" MODIFIED="2011-02-27 18:59:46 +1000" MODIFIED_BY="[Empty name]" NAME="Bembridge 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bembridge G, Garcia-Beato R, Lòpez J, Melero J, Taylor G</AU>
<TI>Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein</TI>
<SO>Journal of Immunology</SO>
<YR>1998</YR>
<VL>161</VL>
<NO>5</NO>
<PG>2473-80</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:06:57 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 00:51:40 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 9725246"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berman-1991" MODIFIED="2011-01-14 11:56:52 +1000" MODIFIED_BY="[Empty name]" NAME="Berman 1991" TYPE="JOURNAL_ARTICLE">
<AU>Berman S</AU>
<TI>Epidemiology of acute respiratory infections in children of developing countries</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>Suppl 6</NO>
<PG>454-62</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:42:53 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:42:53 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="1862276"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Binn-2007" MODIFIED="2011-02-27 19:00:00 +1000" MODIFIED_BY="[Empty name]" NAME="Binn 2007" TYPE="JOURNAL_ARTICLE">
<AU>Binn LN, Sanchez JL, Gaydos JC</AU>
<TI>Emergence of adenovirus type 14 in US military recruits - a new challenge</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>10</NO>
<PG>1436-7</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:50:15 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 00:52:17 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18008220"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-DDCP-2010" MODIFIED="2017-05-15 15:31:57 +1000" MODIFIED_BY="[Empty name]" NAME="DDCP 2010" TYPE="OTHER">
<AU>Division of Disease Control and Prevention, Utah Department of Health</AU>
<TI>Difference between cold and flu symptoms</TI>
<SO>health.utah.gov/epi/diseases/flu/ColdvsFlu.pdf</SO>
<YR>2010 (accessed prior to 12 May 2017)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denny-1983" MODIFIED="2010-09-03 13:16:08 +1000" MODIFIED_BY="Clare Dooley" NAME="Denny 1983" TYPE="JOURNAL_ARTICLE">
<AU>Denny FW, Murphy TF, Clyde WA, Collier AM, Henderson FW</AU>
<TI>Croup: an 11 year study in a pediatric practice</TI>
<SO>Pediatrics</SO>
<YR>1983</YR>
<VL>71</VL>
<NO>6</NO>
<PG>871-6</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:31:17 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:31:17 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6304611"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Edlmayr-2009" MODIFIED="2017-02-08 08:46:40 +1000" MODIFIED_BY="Ann Jones" NAME="Edlmayr 2009" TYPE="JOURNAL_ARTICLE">
<AU>Edlmayr J, Niespodziana K, Linhart B, Focke-Tejk lM, Westrtschnig K, Scheiblhober S, et al</AU>
<TI>A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen PHl p1</TI>
<SO>Journal of Immunology</SO>
<YR>2009</YR>
<VL>182</VL>
<NO>10</NO>
<PG>6298-306</PG>
<IDENTIFIERS MODIFIED="2011-02-27 19:00:08 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 00:53:02 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19414783"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eriksson-2006" MODIFIED="2012-12-11 16:22:34 +1000" MODIFIED_BY="[Empty name]" NAME="Eriksson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Eriksson KK, Makia D, Maier R, Ludewig B, Thiel V</AU>
<TI>Towards a coronavirus-based HIV multigene vaccine</TI>
<SO>Clinical and Developmental Immunology</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>2-4</NO>
<PG>353-60</PG>
<IDENTIFIERS MODIFIED="2011-01-07 04:40:53 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2011-01-07 04:40:53 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17162377"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Esper-2003" MODIFIED="2010-09-06 08:14:55 +1000" MODIFIED_BY="[Empty name]" NAME="Esper 2003" TYPE="JOURNAL_ARTICLE">
<AU>Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS</AU>
<TI>Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>111</VL>
<NO>6 pt 1</NO>
<PG>1407-10</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:22:30 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:22:30 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12777560"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Evans-1997" MODIFIED="2012-12-11 16:22:57 +1000" MODIFIED_BY="[Empty name]" NAME="Evans 1997" TYPE="BOOK">
<AU>Evans AS, Kaslow RA (editors)</AU>
<SO>Viral Infection of Humans: Epidemiology and Control</SO>
<YR>1997</YR>
<EN>4th</EN>
<PB>Plenum Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falsey-2005" MODIFIED="2010-09-06 08:15:12 +1000" MODIFIED_BY="[Empty name]" NAME="Falsey 2005" TYPE="JOURNAL_ARTICLE">
<AU>Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE</AU>
<TI>Respiratory syncytial virus infection in elderly and high-risk adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<NO>17</NO>
<PG>1749-59</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:47:06 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:47:06 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15858184 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fermi-Paradox-2012" MODIFIED="2012-12-11 16:23:27 +1000" MODIFIED_BY="[Empty name]" NAME="Fermi Paradox 2012" TYPE="OTHER">
<TI>Fermi Paradox</TI>
<SO>www.crystalinks.com/fermiparadox.html</SO>
<YR>2012 (accessed 12 July 2012)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freiman-1978" MODIFIED="2012-12-11 16:23:44 +1000" MODIFIED_BY="[Empty name]" NAME="Freiman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR</AU>
<TI>The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>299</VL>
<NO>13</NO>
<PG>690-4</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:18:17 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="355881"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gabriel-2012" MODIFIED="2012-11-29 03:37:50 +1000" MODIFIED_BY="[Empty name]" NAME="Gabriel 2012" TYPE="JOURNAL_ARTICLE">
<AU>Gabriel SE, Normand SL</AU>
<TI>Getting the methods right - the Foundation of Patient-Centered Outcomes Research</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>367</VL>
<NO>9</NO>
<PG>787-90</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:37:50 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-11-29 03:37:50 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1056/NEJMp1207437"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glezen-2000" MODIFIED="2010-09-03 13:22:40 +1000" MODIFIED_BY="Clare Dooley" NAME="Glezen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB</AU>
<TI>Impact of respiratory infection on persons with chronic underlying conditions</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<NO>4</NO>
<PG>499-505</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:12:20 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:12:20 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="10659876"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldsby-2000" MODIFIED="2017-05-15 15:36:49 +1000" MODIFIED_BY="[Empty name]" NAME="Goldsby 2000" TYPE="BOOK_SECTION">
<AU>Goldsby R, Kingt T, Osborne B</AU>
<TI>Overview of the immune system</TI>
<SO>Kuby Immunology</SO>
<YR>2000</YR>
<VL>3</VL>
<EN>4th</EN>
<PB>WH Freeman Co</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gonzales-2001" MODIFIED="2010-09-24 00:50:54 +1000" MODIFIED_BY="[Empty name]" NAME="Gonzales 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gonzales R, Malone DC, Maselli JH, Sande MA</AU>
<TI>Excessive antibiotic use for acute respiratory infections in the United States</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>6</NO>
<PG>757-62</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:50:54 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 00:53:38 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11512079"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gorczynski-2007" MODIFIED="2017-05-15 15:37:42 +1000" MODIFIED_BY="[Empty name]" NAME="Gorczynski 2007" TYPE="BOOK_SECTION">
<AU>Gorczynski R, Stanley J</AU>
<TI>Problem-based immunology</TI>
<TO>Inmunología basaqda en la resolución de problemas</TO>
<SO>Inmunología Basada en Problemas</SO>
<YR>2007</YR>
<VL>138</VL>
<PB>Elsevier Saunders</PB>
<CY>Madrid</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro-GDT-2014" MODIFIED="2017-05-18 09:07:33 +1000" MODIFIED_BY="Liz  Dooley" NAME="GRADEpro GDT 2014" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro GDT</TI>
<YR>2014</YR>
<EN>Accessed: October 15th, 2016</EN>
<PB>GRADE Working Group, McMaster University</PB>
<CY>Hamilton (ON)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gray--2007" MODIFIED="2017-05-15 15:38:35 +1000" MODIFIED_BY="[Empty name]" NAME="Gray  2007" TYPE="JOURNAL_ARTICLE">
<AU>Gray GC, McCarthy T, Lebeck MG, Schnurr OP, Russell KL, Kajon AE, et al</AU>
<TI>Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2007</YR>
<VL>45</VL>
<NO>9</NO>
<PG>1120-31</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:51:16 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 00:54:28 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17918073"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Green-2002" MODIFIED="2012-11-29 03:20:50 +1000" MODIFIED_BY="[Empty name]" NAME="Green 2002" TYPE="JOURNAL_ARTICLE">
<AU>Green SB</AU>
<TI>Design of randomized trials</TI>
<SO>Epidemiologic Reviews</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>1</NO>
<PG>4-11</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:18:03 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="12119855"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gr_x00fc_ber-2008" MODIFIED="2017-05-15 15:39:27 +1000" MODIFIED_BY="[Empty name]" NAME="Grüber 2008" TYPE="JOURNAL_ARTICLE">
<AU>Grüber C, Keil T, Kulig M, Roll S, Wahn U, Wahn V; MAS-90 Study Group</AU>
<TI>History of respiratory infections in the first 12 yr among children from a birth cohort</TI>
<SO>Pediatric Allergy and Immunology</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>6</NO>
<PG>505-12</PG>
<IDENTIFIERS MODIFIED="2017-03-15 08:41:51 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-03-15 08:41:51 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18167154"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gwaltney-1967" MODIFIED="2017-03-15 08:45:03 +1000" MODIFIED_BY="[Empty name]" NAME="Gwaltney 1967" TYPE="JOURNAL_ARTICLE">
<AU>Gwaltney JM, Hendley J, Simon G, Jordan WSJ</AU>
<TI>Rhinovirus infections in an industrial population II. Characteristics of illness and antibody response</TI>
<SO>JAMA</SO>
<YR>1967</YR>
<VL>202</VL>
<NO>6</NO>
<PG>494-500</PG>
<IDENTIFIERS MODIFIED="2017-03-15 08:45:03 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-03-15 08:45:03 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="4293015"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gwaltney-1985" MODIFIED="2010-09-03 13:29:13 +1000" MODIFIED_BY="Clare Dooley" NAME="Gwaltney 1985" TYPE="JOURNAL_ARTICLE">
<AU>Gwaltney JM</AU>
<TI>Virology and immunology of the common cold</TI>
<SO>Rhinology</SO>
<YR>1985</YR>
<VL>23</VL>
<NO>4</NO>
<PG>265-71</PG>
<IDENTIFIERS MODIFIED="2010-08-24 02:58:22 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 02:58:22 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="3001912"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gwaltney-2000" MODIFIED="2017-05-15 15:42:08 +1000" MODIFIED_BY="[Empty name]" NAME="Gwaltney 2000" TYPE="BOOK_SECTION">
<AU>Gwaltney JM</AU>
<TI>The common cold</TI>
<SO>Principles and Practices of Infectious Diseases</SO>
<YR>2000</YR>
<PG>651-6</PG>
<EN>5th</EN>
<ED>Mandell GL, Bennett JE, Dolin R</ED>
<PB>Churchill Livingstone</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hall-2001" MODIFIED="2011-02-27 19:01:53 +1000" MODIFIED_BY="[Empty name]" NAME="Hall 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hall CV</AU>
<TI>Respiratory syncytial virus and parainfluenza virus</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>25</NO>
<PG>1917-28</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:06:27 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:06:27 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11419430"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harrison-2008" MODIFIED="2012-12-11 16:28:26 +1000" MODIFIED_BY="[Empty name]" NAME="Harrison 2008" TYPE="BOOK">
<AU>Fauci AS, Brownwald E, Kasper D, Hauser S, Longo D, Hameson L, et al</AU>
<SO>Harrison Principios de Medicina Interna</SO>
<YR>2008</YR>
<EN>17th</EN>
<PB>McGraw Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heikkinen-2003" MODIFIED="2013-06-04 20:23:20 +1000" MODIFIED_BY="[Empty name]" NAME="Heikkinen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heikkinen T, Jarvinen A</AU>
<TI>The common cold</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9351</NO>
<PG>51-9</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:51:39 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 00:56:41 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12517470"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henrickson-1994" MODIFIED="2011-02-27 19:02:11 +1000" MODIFIED_BY="[Empty name]" NAME="Henrickson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Henrickson KJ, Kuhn SM, Savatski LL</AU>
<TI>Epidemiology and cost of infection with human parainfluenza viruses types 1 and 2 in young children</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>5</NO>
<PG>770-9</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:39:50 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:39:50 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8075269"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henrickson-2003" MODIFIED="2017-03-15 08:47:53 +1000" MODIFIED_BY="[Empty name]" NAME="Henrickson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Henrickson KJ</AU>
<TI>Parainfluenza viruses</TI>
<SO>Clinical Microbiology Reviews</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>2</NO>
<PG>242-64</PG>
<IDENTIFIERS MODIFIED="2017-03-15 08:47:53 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-03-15 08:47:53 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12692097"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2017-05-15 15:47:18 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hussell-1998" MODIFIED="2010-09-03 13:56:09 +1000" MODIFIED_BY="Clare Dooley" NAME="Hussell 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hussell T, Georgiou A, Sparer T, Matthews S, Pala P, Openshaw P</AU>
<TI>Host genetic determinants of vaccine-induced eosinophilia during RSV infection</TI>
<SO>Journal of Immunology</SO>
<YR>1998</YR>
<VL>161</VL>
<NO>11</NO>
<PG>6215-22</PG>
<IDENTIFIERS MODIFIED="2010-07-02 01:12:02 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 01:12:02 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9834108"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2017-05-15 15:47:59 +1000" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>10</NO>
<PG>781-8</PG>
<IDENTIFIERS MODIFIED="2012-11-22 23:35:56 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15545678"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2017-03-15 08:54:38 +1000" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>Meta-research: the art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS MODIFIED="2017-03-15 08:54:38 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-03-15 08:54:38 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="26061464"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jackson-2008" MODIFIED="2017-05-15 15:48:28 +1000" MODIFIED_BY="[Empty name]" NAME="Jackson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, et al</AU>
<TI>Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2008</YR>
<VL>178</VL>
<NO>7</NO>
<PG>667-72</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:51:01 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:51:01 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18565953"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2011" MODIFIED="2017-05-15 15:48:46 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2011" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al</AU>
<TI>Physical interventions to interrupt or reduce the spread of respiratory viruses</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2012-12-10 10:36:15 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-12-10 10:36:15 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006207.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jefferson-2012" MODIFIED="2012-12-10 10:27:57 +1000" MODIFIED_BY="[Empty name]" NAME="Jefferson 2012" TYPE="COCHRANE_REVIEW">
<AU>Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V</AU>
<TI>Vaccines for preventing influenza in healthy children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>8</NO>
<IDENTIFIERS MODIFIED="2012-12-10 10:26:50 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-12-10 10:26:50 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004879.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kahn-2003" MODIFIED="2010-09-06 08:18:18 +1000" MODIFIED_BY="[Empty name]" NAME="Kahn 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kahn JS</AU>
<TI>Human metapneumovirus: a newly emerging respiratory pathogen</TI>
<SO>Current Opinion in Infection Diseases</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>3</NO>
<PG>255-8</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:19:13 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:19:13 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12821817"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kang-2009" MODIFIED="2010-07-02 01:15:28 +1000" MODIFIED_BY="[Empty name]" NAME="Kang 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kang SM, Compans RW</AU>
<TI>Host responses from innate to adaptive immunity after vaccination: molecular and cellular events</TI>
<SO>Molecular Cell</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>1</NO>
<PG>5-14</PG>
<IDENTIFIERS MODIFIED="2010-07-02 01:15:28 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 01:15:28 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19214429"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kirby-2002" MODIFIED="2012-12-11 16:34:17 +1000" MODIFIED_BY="[Empty name]" NAME="Kirby 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kirby A, Gebski V, Keech AC</AU>
<TI>Determining the sample size in a clinical trial</TI>
<SO>Medical Journal of Australia</SO>
<YR>2002</YR>
<VL>177</VL>
<NO>5</NO>
<PG>256-7</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:18:50 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="12197821"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krasinski-1985" MODIFIED="2013-06-04 19:58:45 +1000" MODIFIED_BY="[Empty name]" NAME="Krasinski 1985" TYPE="JOURNAL_ARTICLE">
<AU>Krasinski K</AU>
<TI>Severe respiratory syncytial virus infection: clinical features, nosocomial acquisition and outcome</TI>
<SO>Pediatric Infectious Disease</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>3</NO>
<PG>250-7</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:33:40 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:33:40 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="4000987"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Larson-1980" MODIFIED="2010-09-03 14:01:13 +1000" MODIFIED_BY="Clare Dooley" NAME="Larson 1980" TYPE="JOURNAL_ARTICLE">
<AU>Larson HE, Reed SE, Tyrrell DA</AU>
<TI>Isolation of rhinoviruses and coronaviruses from 38 colds in adults</TI>
<SO>Journal of Medical Virology</SO>
<YR>1980</YR>
<VL>5</VL>
<NO>3</NO>
<PG>221-9</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:07:55 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:07:55 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="6262450"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lau-2006" MODIFIED="2017-05-15 15:51:23 +1000" MODIFIED_BY="[Empty name]" NAME="Lau 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lau S, Woo P, Yip L, Tse H, Tesoi H, Ching V, et al</AU>
<TI>Coronavirus HKU1 and other coronavirus infection in Hong Kong</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>6</NO>
<PG>2063-71</PG>
<IDENTIFIERS MODIFIED="2010-09-23 23:40:31 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-23 23:40:31 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16757599"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leder-2003" MODIFIED="2017-05-15 15:52:16 +1000" MODIFIED_BY="[Empty name]" NAME="Leder 2003" TYPE="JOURNAL_ARTICLE">
<AU>Leder K, Sinclair MI, Mitakakis TZ, Hellard ME, Forbes A</AU>
<TI>A community-based study of respiratory episodes in Melbourne, Australia</TI>
<SO>Australian and New Zealand Journal of Public Health</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>4</NO>
<PG>399&#8211;404</PG>
<IDENTIFIERS MODIFIED="2017-03-15 08:58:12 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-03-15 08:58:12 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14705301"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lemanske-2005" MODIFIED="2017-05-15 15:52:42 +1000" MODIFIED_BY="[Empty name]" NAME="Lemanske 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al</AU>
<TI>Rhinovirus illnesses during infancy predict subsequent childhood wheezing</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>2005</YR>
<VL>116</VL>
<NO>3</NO>
<PG>571-7</PG>
<IDENTIFIERS MODIFIED="2010-08-24 02:48:17 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 02:48:17 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16159626"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2017-05-15 15:53:16 +1000" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:18:31 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="9746022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2017-02-08 13:15:40 +1000" MODIFIED_BY="Ann Jones" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>339</VL>
<PG>2535</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2017-05-15 15:53:54 +1000" MODIFIED_BY="[Empty name]" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c869</PG>
<IDENTIFIERS MODIFIED="2012-11-22 23:33:32 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="20332511"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monto-1993" MODIFIED="2011-02-27 19:02:39 +1000" MODIFIED_BY="[Empty name]" NAME="Monto 1993" TYPE="JOURNAL_ARTICLE">
<AU>Monto AS, Sullivan KM</AU>
<TI>Acute respiratory illness in the community. Frequency of illness and the agents involved</TI>
<SO>Epidemiology and Infection</SO>
<YR>1993</YR>
<VL>110</VL>
<NO>1</NO>
<PG>145-60</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:02:05 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:02:05 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="8432318"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00e4_kel_x00e4_-1998" MODIFIED="2017-05-15 15:54:59 +1000" MODIFIED_BY="[Empty name]" NAME="Mäkelä 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al</AU>
<TI>Viruses and bacteria in the etiology of the common cold</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>1998</YR>
<VL>36</VL>
<NO>2</NO>
<PG>539-42</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:05:28 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:05:28 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="9466772"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nebeker-2004" MODIFIED="2010-09-24 03:49:00 +1000" MODIFIED_BY="[Empty name]" NAME="Nebeker 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nebeker JR, Barach P, Samore MH</AU>
<TI>Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>10</NO>
<PG>795-801</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:49:00 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-03-08 11:37:22 +1000" MODIFIED_BY="MARIA LUISA " TYPE="MEDLINE" VALUE="15148066"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nelson-2000" MODIFIED="2017-05-15 15:57:15 +1000" MODIFIED_BY="[Empty name]" NAME="Nelson 2000" TYPE="BOOK">
<AU>Kliegman R, Behrman RE, Jenson HB</AU>
<SO>Nelson Tratado de Pediatría</SO>
<YR>2000</YR>
<EN>16th</EN>
<PB>McGraw Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-1997" MODIFIED="2010-09-24 03:51:39 +1000" MODIFIED_BY="[Empty name]" NAME="Nicholson 1997" TYPE="JOURNAL_ARTICLE">
<AU>Nicholson KG, Kent J, Hammersley V, Cancio E</AU>
<TI>Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective population based study of disease burden</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7115</NO>
<PG>1060-4</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:51:39 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Nissen-2002" MODIFIED="2013-06-04 20:23:51 +1000" MODIFIED_BY="Clare Dooley" NAME="Nissen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Nissen MD, Siebert DJ, Mackay IM, Sloots TP, Withers SJ</AU>
<TI>Evidence of human metapneumovirus in Australian children</TI>
<SO>Medical Journal of Australia</SO>
<YR>2002</YR>
<VL>176</VL>
<NO>4</NO>
<PG>188</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:16:10 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:16:10 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="11913922"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Palmemberg--2009" MODIFIED="2017-05-15 16:02:49 +1000" MODIFIED_BY="[Empty name]" NAME="Palmemberg  2009" TYPE="JOURNAL_ARTICLE">
<AU>Palmemberg AC, Spiro D, Kuzmickas R, Wang S, Djikeng A, Rathe JA, et al</AU>
<TI>Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution</TI>
<SO>Science</SO>
<YR>2009</YR>
<VL>324</VL>
<NO>5923</NO>
<PG>55-9</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:51:07 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 01:22:15 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19213880"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peltola-2008" MODIFIED="2011-02-27 19:02:59 +1000" MODIFIED_BY="[Empty name]" NAME="Peltola 2008" TYPE="JOURNAL_ARTICLE">
<AU>Peltola V, Waris M, Osterback R, Susi P, Hyypiä T, Ruuskanen O</AU>
<TI>Clinical effects of rhinovirus infections</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>4</NO>
<PG>411-4</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:36:44 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:36:44 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18835215"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pichichero-2009" MODIFIED="2010-09-24 03:51:20 +1000" MODIFIED_BY="[Empty name]" NAME="Pichichero 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pichichero ME</AU>
<TI>Booster vaccinations: can immunologic memory outpace disease pathogenesis?</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<NO>6</NO>
<PG>1633-41</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:51:20 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-24 03:51:16 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19933727"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Plotkin--2008" MODIFIED="2010-09-24 03:50:56 +1000" MODIFIED_BY="[Empty name]" NAME="Plotkin  2008" TYPE="JOURNAL_ARTICLE">
<AU>Plotkin SA</AU>
<TI>Vaccines: correlates of vaccine-induced immunity</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>3</NO>
<PG>401-9</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:50:56 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-24 03:50:54 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18558875"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Poland-2009" MODIFIED="2010-09-24 03:50:15 +1000" MODIFIED_BY="[Empty name]" NAME="Poland 2009" TYPE="JOURNAL_ARTICLE">
<AU>Poland G, Barry MA</AU>
<TI>Common cold, uncommon variation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2009</YR>
<VL>360</VL>
<NO>21</NO>
<PG>2245-6</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:50:15 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-24 03:50:14 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="19458372"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Regamey-2008" MODIFIED="2010-09-06 08:21:15 +1000" MODIFIED_BY="[Empty name]" NAME="Regamey 2008" TYPE="JOURNAL_ARTICLE">
<AU>Regamey N, Kaiser L</AU>
<TI>Rhinovirus infections in infants: is respiratory syncytial virus ready for the challenge?</TI>
<SO>European Respiratory Journal</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>2</NO>
<PG>249-51</PG>
<IDENTIFIERS MODIFIED="2010-08-24 02:51:47 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 02:51:47 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="18669781"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ren-2017" MODIFIED="2017-05-15 16:06:39 +1000" MODIFIED_BY="[Empty name]" NAME="Ren 2017" TYPE="JOURNAL_ARTICLE">
<AU>Ren L, Yang D, Ren X, Li M, Mu X, Wang Q, et al</AU>
<TI>Genotyping of human rhinovirus in adult patients with acute respiratory infections identified predominant infections of genotype A21</TI>
<SO>Scientific Reports</SO>
<YR>2017</YR>
<VL>7</VL>
<PG>41601</PG>
<IDENTIFIERS MODIFIED="2017-03-15 09:04:59 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-03-15 09:04:59 +1000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="28128353"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2017-02-08 13:26:46 +1000" MODIFIED_BY="Ann Jones" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager 5 (RevMan 5)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rey_x002d_Jurado-2017" MODIFIED="2017-05-15 16:10:11 +1000" MODIFIED_BY="[Empty name]" NAME="Rey-Jurado 2017" TYPE="JOURNAL_ARTICLE">
<AU>Rey-Jurado E, Kalergis AM</AU>
<TI>Immunological features of respiratory syncytial virus-caused pneumonia - implications for vaccine design</TI>
<SO>International Journal of Molecular Sciences</SO>
<YR>2017</YR>
<VL>18</VL>
<NO>3</NO>
<PG>556</PG>
<IDENTIFIERS MODIFIED="2017-05-15 16:08:22 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-05-15 16:08:22 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.3390/ijms18030556"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Risnes-2005" MODIFIED="2011-02-27 19:42:55 +1000" MODIFIED_BY="[Empty name]" NAME="Risnes 2005" TYPE="JOURNAL_ARTICLE">
<AU>Risnes KR, Radtke A, Nordbø SA, Grammeltvedt AT, Døllner H</AU>
<TI>Human metapneumovirus - occurrence and clinical significance</TI>
<SO>Tidsskrift for den Norske Lægeforening</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>2769-72</PG>
<IDENTIFIERS MODIFIED="2010-08-24 03:57:31 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 03:57:31 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16244677"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roitt-2004" MODIFIED="2017-05-15 16:10:57 +1000" MODIFIED_BY="[Empty name]" NAME="Roitt 2004" TYPE="BOOK_SECTION">
<AU>Roitt I, Delves P</AU>
<TI>Glossary</TI>
<SO>Essential Immunology</SO>
<YR>2004</YR>
<VL>466</VL>
<EN>10th</EN>
<PB>Blackwell</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roxas-2007" MODIFIED="2011-02-27 19:03:27 +1000" MODIFIED_BY="[Empty name]" NAME="Roxas 2007" TYPE="JOURNAL_ARTICLE">
<AU>Roxas M, Jurenka J</AU>
<TI>Colds and influenza: a review of diagnosis and conventional, botanical and nutritional considerations</TI>
<SO>Alternative Medicine Review</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>1</NO>
<PG>25-48</PG>
<IDENTIFIERS MODIFIED="2010-09-24 03:49:29 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-09-24 03:49:28 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="17397266"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Russell--2006" MODIFIED="2017-05-15 16:11:40 +1000" MODIFIED_BY="[Empty name]" NAME="Russell  2006" TYPE="JOURNAL_ARTICLE">
<AU>Russell KL, Hawksworth AW, Ryan MA, Strickler J, Irvine M, Hansen CJ, et al</AU>
<TI>Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004</TI>
<SO>Vaccine</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>15</NO>
<PG>2835-42</PG>
<IDENTIFIERS MODIFIED="2011-01-14 12:02:37 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 01:27:12 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="16480793"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2012-11-29 03:20:28 +1000" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS MODIFIED="2012-11-29 03:17:49 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="7823387"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2003" MODIFIED="2010-09-03 19:48:38 +1000" MODIFIED_BY="Clare Dooley" NAME="Thompson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WW</AU>
<TI>Mortality associated with influenza and respiratory syncytial virus in the United States</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>2</NO>
<PG>179-86</PG>
<IDENTIFIERS MODIFIED="2010-08-24 01:26:44 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-08-24 01:26:44 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="12517228"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tobin--2008" MODIFIED="2017-05-15 16:12:22 +1000" MODIFIED_BY="[Empty name]" NAME="Tobin  2008" TYPE="JOURNAL_ARTICLE">
<AU>Tobin G, Trujillo JD, Bushnell R, Lin G, Chaudhuri RA, Largo J, et al</AU>
<TI>Deceptive imprinting and immune refocusing in vaccine design</TI>
<SO>Vaccine</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>49</NO>
<PG>6189-99</PG>
<IDENTIFIERS MODIFIED="2011-01-14 12:02:49 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wat--2004" MODIFIED="2010-09-24 00:53:03 +1000" MODIFIED_BY="[Empty name]" NAME="Wat  2004" TYPE="JOURNAL_ARTICLE">
<AU>Wat D</AU>
<TI>The common cold: a review of the literature</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>2</NO>
<PG>79-88</PG>
<IDENTIFIERS MODIFIED="2010-09-24 00:53:03 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-07-02 01:28:15 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15172021"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2017-05-15 16:16:29 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Felix-2011" MODIFIED="2017-05-15 16:16:29 +1000" MODIFIED_BY="[Empty name]" NAME="Felix 2011" TYPE="COCHRANE_REVIEW">
<AU>Felix ML, Guerra CV, Hinojosa MA, Cabezas CI, Hidalgo R, Samaniego DH, et al</AU>
<TI>Vaccines for the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2017-03-03 04:56:33 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002190.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Simancas_x002d_Racines-2013" MODIFIED="2017-02-05 00:17:32 +1000" MODIFIED_BY="[Empty name]" NAME="Simancas-Racines 2013" TYPE="COCHRANE_REVIEW">
<AU>Simancas-Racines D, Guerra CV, Hidalgo R</AU>
<TI>Vaccines for the common cold</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<PG>CD002190</PG>
<IDENTIFIERS MODIFIED="2017-02-05 00:17:32 +1000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-02-05 00:17:32 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002190.pub4"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-03-12 10:31:33 +1000" MODIFIED_BY="Clare Dooley"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2017-05-18 09:11:06 +1000" MODIFIED_BY="Liz  Dooley">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2017-05-18 09:11:06 +1000" MODIFIED_BY="Liz  Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2017-05-18 09:10:30 +1000" MODIFIED_BY="Liz  Dooley" STUDY_ID="STD-Griffin-1970">
<CHAR_METHODS MODIFIED="2017-05-15 14:25:17 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Design:</B> double-blind, RCT (2 arms)<BR/>
</P>
<P>
<B>Country:</B> USA (1 site)</P>
<P>
<B>Clinical setting:</B> Great Lakes Naval Training Center</P>
<P>
<B>Follow-up:</B> 9 weeks' basic-training period</P>
<P>
<B>Intention-to-treat:</B> yes</P>
<P>
<B>Randomisation unit:</B> participant</P>
<P>
<B>Analysis unit:</B> participant</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2017-05-18 09:10:18 +1000" MODIFIED_BY="Liz  Dooley">
<P>Great Lakes Naval Training Center, new recruits</P>
<P>Randomised: 2307 participants</P>
<P>Vaccines group: 1139 (49.3%)<BR/>Placebo group: 1168 (50.7%)</P>
<P>
<BR/>Participants receiving intervention: 1139</P>
<P>Vaccines group: 1139 (49.3%)<BR/>Placebo group: 1168 (50.7%)</P>
<P> </P>
<P>Lost post-randomisation: 0%</P>
<P>Analysed participants:</P>
<P>Vaccines group: 1139 (49.3%)<BR/>Placebo group: 1168 (50.7%)<BR/>
<BR/>
</P>
<P>Age median (mean (SD)): did not report</P>
<P>Gender (number of men): did not report</P>
<P>Inclusion criteria:</P>
<OL>
<LI>Aged 17 to 20 years</LI>
<LI>Great Lakes Naval Training Center, new recruits</LI>
</OL>
<P>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2017-05-18 09:10:30 +1000" MODIFIED_BY="Liz  Dooley">
<P>Experimental group: the vaccines used were composed of orally administered live adenovirus 4, parenterally administered inactivated adenovirus 4, and parenterally administered inactivated adenovirus 4 and 7 preparations</P>
<P>
<BR/>
</P>
<P>Control group: placebo</P>
<P>
<BR/>
</P>
<P>Co-interventions</P>
<OL>
<LI>1.2 million units of benzathine penicillin G</LI>
<LI>polyvalent influenza vaccine</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2017-05-15 14:28:56 +1000" MODIFIED_BY="[Empty name]">
<P>This RCT did not specify primary or secondary outcomes.<BR/>
<BR/>
</P>
<P>Incidence of admissions of participants with respiratory illness (not only hospitalised participants)</P>
<OL>
<LI>Acute undifferentiated respiratory disease</LI>
<LI>Common cold syndrome: an acute inflammation of the upper respiratory tract with coryza as a prominent feature and temperature, taken orally, of 100º F or less on admission</LI>
<LI>Exudative pharyngitis</LI>
<LI>Atypical pneumonia</LI>
<LI>Viral exanthem</LI>
</OL>
<P>Toxic effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2017-05-15 14:30:47 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Trial registration: not reported</LI>
<LI>A priori sample size estimation: not reported</LI>
<LI>Conducted: from 19 February to 16 April, and observations continued to 20 June 1965</LI>
<LI>Funder: "This investigation was supported in part by the Department of the Navy, research project MF 022.03.07-4014, and in part by the Public Health Service Vaccine Development Branch, contract 43-65-1031" (p. 981)</LI>
<LI>Role of funder: "Capt. Robert O. Peckinpaugh, MC, USN; LCDR Wayne E. Frazier, MC, USN; and Willard E. Pierce aided in the design, conduct, and statistical interpretation of this investigation" (p. 981)</LI>
<LI>Declared conflicts of interest: "The opinions and assertions contained here in are those of the authors and are not to be construed as official or as reflecting the views of the Navy Department or the Naval Service at large." (p. 981)</LI>
</OL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2017-05-15 14:37:50 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:37:52 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Belshe-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:37:52 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:30:48 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Belshe-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:30:48 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:30:38 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Belshe-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:30:38 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:30:28 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Belshe-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:30:28 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:37:57 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Clements-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:37:57 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:30:17 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-DeVincenzo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:30:17 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:38:09 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Doggett-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:38:09 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:38:13 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Dudding-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:38:13 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:30:07 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Falsey-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:30:07 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:29:56 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Falsey-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:29:56 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not include healthy people</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:38:25 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Fulginiti-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:38:25 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:29:42 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Glenn-2016">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:29:42 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:29:31 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Gomez-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:29:31 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:29:24 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Gonzalez-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:29:24 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:29:14 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Greenberg-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:29:14 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Included participants aged &lt; 6 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:39:11 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Hamory-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:39:11 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:29:06 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Karron-1995a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:29:06 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:28:55 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Karron-1995b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:28:55 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:39:27 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Karron-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:39:27 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:28:43 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Karron-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:28:43 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:28:34 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Karron-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:28:34 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:28:24 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Karron-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:28:24 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:28:16 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Kumpu-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:28:16 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate a vaccine (evaluated a probiotic)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:28:05 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Langley-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:28:05 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:27:57 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Lee-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:27:57 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Included participants aged &lt; 6 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-05-15 14:37:50 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-05-15 14:37:50 +1000" MODIFIED_BY="[Empty name]">
<P>Non-vaccine interventions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:27:48 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Lin-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:27:48 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:27:38 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Lyons-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:27:38 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:27:24 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Madhi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:27:24 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Included participants aged &lt; 6 months</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:27:14 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Munoz-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:27:14 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Included pregnant women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-04 22:29:40 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-04 22:29:40 +1000" MODIFIED_BY="[Empty name]">
<P>Update on vaccines topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:27:03 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Paradiso-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:27:03 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:26:54 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Piedra-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:26:54 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:26:44 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Pierce-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:26:44 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:26:35 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Power-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:26:35 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:40:56 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Ritchie-1958">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:40:56 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-29 10:07:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simoes-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-29 10:07:02 +1000" MODIFIED_BY="[Empty name]">
<P>Meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:26:23 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Tang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:26:23 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:26:14 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Top-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:26:14 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:26:05 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Tristram-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:26:05 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:41:14 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Watt-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:41:14 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 14:25:56 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Welliver-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 14:25:56 +1000" MODIFIED_BY="Ann Jones">
<P>RCT. Did not evaluate common cold</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:41:22 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Wilson-1960">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:41:22 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2017-02-08 13:41:29 +1000" MODIFIED_BY="Ann Jones" STUDY_ID="STD-Wright-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2017-02-08 13:41:29 +1000" MODIFIED_BY="Ann Jones">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-02-26 17:32:55 +1000" MODIFIED_BY="Clare Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-03-12 10:31:33 +1000" MODIFIED_BY="Clare Dooley" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2017-05-18 09:11:06 +1000" MODIFIED_BY="Liz  Dooley">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2017-05-15 14:31:30 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-15 14:31:30 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>Quote: "Epidemiologic design of this study consisted of the random assignment of one half of the recruits ..." (p. 982). Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2017-02-08 14:42:05 +1000" MODIFIED_BY="Ann Jones" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-02-08 14:42:05 +1000" MODIFIED_BY="Ann Jones" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-03-12 10:31:33 +1000" MODIFIED_BY="Clare Dooley" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2017-05-18 09:11:03 +1000" MODIFIED_BY="Liz  Dooley" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2017-05-18 09:11:03 +1000" MODIFIED_BY="Liz  Dooley" RESULT="YES" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>Quote: "Double-blind procedure was followed with paramedical personnel administering the appropriate vaccine or placebo to recruits on their third day after arrival at Great Lakes, just prior to initiation of basic training" (p. 982)</P>
<P>Quote: "Placebo for the parenterally administered vaccines consisted of an injection of physiological saline, and that for the orally administered vaccine consisted of an identical appearing inert gelatin capsule" (p. 982)</P>
<P>Comment: Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2017-05-18 09:11:01 +1000" MODIFIED_BY="Liz  Dooley" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2017-05-18 09:11:01 +1000" MODIFIED_BY="Liz  Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>Quote: "Since recruits with the common cold syndrome rarely require hospitalizations, the effect of the adenovirus vaccines on this clinical entity can not be adequately evaluated."</P>
<P>Comment: Although placebo was used, there could be a risk of detection bias because common cold does not require hospitalization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2017-02-08 14:41:40 +1000" MODIFIED_BY="Ann Jones" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2017-02-08 14:41:40 +1000" MODIFIED_BY="Ann Jones" RESULT="UNKNOWN" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2017-05-15 14:34:22 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-15 14:34:22 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>Comment: The study protocol is not available, but it is clear that the published reports include all expected outcomes. However, some are described in a narrative fashion and not per group.</P>
<P>Quote: "... there was no observable toxic reaction to this new live vaccine preparation within the study design." (p. 985)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2017-05-18 09:11:06 +1000" MODIFIED_BY="Liz  Dooley" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2017-05-18 09:11:06 +1000" MODIFIED_BY="Liz  Dooley" RESULT="NO" STUDY_ID="STD-Griffin-1970">
<DESCRIPTION>
<P>The sample size was not reported. There is no table with basal characteristics of the participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2017-05-15 14:50:36 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2017-05-15 14:50:36 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-06-04 19:58:46 +1000" MODIFIED_BY="Grade Profiler">Virus vaccines compared to placebo for preventing the common cold in healthy people</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Virus vaccines compared to placebo for preventing the common cold in healthy people</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>
<B>Patient or population:</B> healthy people<BR/>
<B>Settings:</B> outpatients at Great Lakes Naval Training Center<BR/>
<B>Intervention:</B> virus vaccines for preventing the common cold¹<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No. of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Virus vaccines for preventing the common cold</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>Incidence of the common cold</B>
<BR/>Number of participants with common cold by group<BR/>Follow-up: mean 9 weeks</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
<BR/>(0.45 to 2.02)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>2307<BR/>(1 study)²</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>³ &#8308; 
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>12 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(5 to 24)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vaccine safety</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="3" VALIGN="TOP">
<P>The study stated that there were no adverse events related to the vaccine.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>2307<BR/>(1 study)²</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>³ &#8309;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Mortality related to the vaccine</B> - not reported</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The included study did not report this outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7" VALIGN="TOP">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Adenovirus vaccine used for preventing the common cold.<BR/>
<SUP>2</SUP>
<LINK REF="STD-Griffin-1970" TYPE="STUDY">Griffin 1970</LINK>.<BR/>
<SUP>3</SUP>Downgraded one level due to high risk of bias for this outcome.<BR/>
<SUP>4</SUP>Downgraded one level due to imprecision: few events (N = 27) and wide 95% confidence interval.<BR/>
<SUP>5</SUP>Downgraded one level due to imprecision: zero events reported in a narrative fashion.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-12-04 22:48:28 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-06-05 22:53:10 +1000" MODIFIED_BY="Clare Dooley">
<COMPARISON ID="CMP-001" MODIFIED="2013-06-05 22:53:10 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adenovirus vaccines versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.016810933079713" CI_START="0.4495765845861245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9522137213094193" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.3046651869738832" LOG_CI_START="-0.34719631632212516" LOG_EFFECT_SIZE="-0.02126556467412094" METHOD="MH" MODIFIED="2013-06-05 22:53:10 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8982446275163086" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1139" TOTAL_2="1168" WEIGHT="100.0" Z="0.12787912972752327">
<NAME>Incidence of the common cold</NAME>
<GROUP_LABEL_1>Vaccines</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Vaccines</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.016810933079713" CI_START="0.4495765845861245" EFFECT_SIZE="0.9522137213094193" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="14" LOG_CI_END="0.3046651869738832" LOG_CI_START="-0.34719631632212516" LOG_EFFECT_SIZE="-0.02126556467412094" MODIFIED="2013-06-05 22:53:10 +1000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.3829066738025573" STUDY_ID="STD-Griffin-1970" TOTAL_1="1139" TOTAL_2="1168" VAR="0.14661752084253799" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2017-05-18 09:11:07 +1000" MODIFIED_BY="Liz  Dooley">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2017-05-15 16:19:20 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAkYAAAI1CAYAAAAzazUDAABKl0lEQVR42u3dD2RV/+PH8Q9JkiQy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2017-05-18 09:11:07 +1000" MODIFIED_BY="Liz  Dooley" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2017-05-18 09:11:07 +1000" MODIFIED_BY="Liz  Dooley" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for the included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASoAAAFzCAIAAAAG2dNHAAAP80lEQVR42u3du25d1RbGcUtIiMJF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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-03-12 10:31:33 +1000" MODIFIED_BY="Clare Dooley"/>
<APPENDICES MODIFIED="2017-05-18 07:26:20 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2017-05-18 07:26:20 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2017-03-22 10:48:33 +1000" MODIFIED_BY="[Empty name]">Glossary</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-16 09:50:03 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="13">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Term</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Definition</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Reference</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Common cold</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The common cold is a self limiting acute upper respiratory tract infection, characterised by rhinorrhoea, nasal congestion, sneezing, cough, sore throat, fever, and malaise.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vaccination</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Inoculation with a vaccine, i.e. a preparation of microbial antigen often combined with adjuvants administered to an individual in order to induce protective immunity against microbial infections. The antigen may be in the form of live, avirulent micro-organisms or purified macromolecular components of micro-organisms.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Immune system</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The collection of cells, tissues, and molecules that mediate resistance to infections</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Cell-mediated immunity</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The arm of the adaptative immune response whose role is to combat infections by intracellular microbes. This type of immunity is mediated by T lymphocytes.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antigenical variability</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Microbes have evolved mechanisms to evade immunity. Many bacteria and viruses mutate their antigenic surface molecules and can no longer be recognised by antibodies produced in response to previous infection.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Serotypes</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>An antigenically distinct subset of a species of an infectious organism that is distinguished from other subsets by serologic (i.e. serum antibody) tests. Humoral immune response to one serotype of microbes, e.g. influenza virus, may not be protective against another serotypes.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Immune responses</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Once a foreign organism has been recognised, the immune system enlists the participation of a variety of cells and molecules to mount an appropriate response in order to eliminate or neutralise the organism.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Goldsby-2000" TYPE="REFERENCE">Goldsby 2000</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antigenic molecules</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Any molecule capable of being recognised by an antibody or T-cell receptor. Any substance that elicits an immune response.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Goldsby-2000" TYPE="REFERENCE">Goldsby 2000</LINK>; <LINK REF="REF-Roitt-2004" TYPE="REFERENCE">Roitt 2004</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Allergens</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>An antigen that elicits an immediate hypersensitivity (allergic) reaction. Allergens are proteins, or chemicals bound to proteins, that induce immunoglobulin E antibody production in atopic individuals.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Immunopotentiation</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Non-specific immunostimulation given by various agents that can stimulate the immune response. It is believed that the mechanism of action is through some modification of local cytokines or growth of innate immune mechanisms.<BR/>
</P>
<P>An increase in the functional capacity of the immune response</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Gorczynski-2007" TYPE="REFERENCE">Gorczynski 2007</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Opsonisation</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The process by which particulate antigens are rendered more susceptible to phagocytosis</P>
<P>The process of attaching opsonins, such as immunoglobulin G or complement fragments, to microbial surfaces to target microbes for phagocytosis</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>; <LINK REF="REF-Goldsby-2000" TYPE="REFERENCE">Goldsby 2000</LINK>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Phagocytosis</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Macrophages are capable of ingesting and digesting exogenous antigens, such as whole micro-organisms and insoluble particles, and endogenous matter, such as injured or dead host cells, cellular debris, and activated clotting factors.</P>
<P>The process by which certain cells of the innate immune system, including macrophages and neutrophils, engulf large particles (&gt; 0.5 µm diameter), such as intact microbes. The cell surrounds the particle by a cytoskeleton-dependent process, leading to formation of an intracellular vesicle called a phagosome, which contains the ingested particle.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Abbas-2001" TYPE="REFERENCE">Abbas 2001</LINK>; <LINK REF="REF-Goldsby-2000" TYPE="REFERENCE">Goldsby 2000</LINK>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2017-05-18 07:26:20 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-06-04 19:30:02 +1000" MODIFIED_BY="[Empty name]">Differences between clinical characteristics of the common cold and influenza</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-15 16:31:41 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="14">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Feature</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Common cold</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Influenza</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>References</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Aetiological agent</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; 100 viral strains; rhinovirus most common</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>3 strains of influenza virus: influenza A, B, C</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="13" VALIGN="TOP">
<P>
<LINK REF="REF-DDCP-2010" TYPE="REFERENCE">DDCP 2010</LINK>; <LINK REF="REF-Gwaltney-1967" TYPE="REFERENCE">Gwaltney 1967</LINK>; <LINK REF="REF-Gwaltney-2000" TYPE="REFERENCE">Gwaltney 2000</LINK>;</P>
<P>
<LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>;</P>
<P>
<LINK REF="REF-Roxas-2007" TYPE="REFERENCE">Roxas 2007</LINK>; <LINK REF="REF-Thompson-2003" TYPE="REFERENCE">Thompson 2003</LINK>
</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Site of infection</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Upper respiratory tract</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Entire respiratory system</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Symptom onset</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Gradual: 1 to 3 days</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sudden: within a few hours</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fever, chills</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Occasional, low grade (&lt; 100º F)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fever is usually present with the flu, in up to 80% of all flu cases. A temperature of 100º F or higher for 3 to 4 days is typically associated with the flu.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Headache</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Frequent, usually mild</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Characteristic, more severe</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>General aches, pains</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mild, if any</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Characteristic, often severe and affecting the entire body</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cough, chest congestion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mild to moderate, with hacking cough</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Common, may become severe</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sore throat</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Common, usually mild</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sometimes present</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Runny, stuffy nose</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Very common, accompanied by bouts of sneezing</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Sometimes present</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Fatigue, weakness</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Mild, if any</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual, may be severe and last 2 to 3 weeks</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Extreme exhaustion</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Never</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Frequent, usually in early stages of illness</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Season</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Year around, peaks in winter months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Most cases between November and February</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Antibiotics helpful</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No, unless secondary bacterial infection develops</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No, unless secondary bacterial infection develops</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2017-05-18 07:26:17 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-12-04 22:34:44 +1000" MODIFIED_BY="[Empty name]">Viral causes of the common cold</TITLE>
<APPENDIX_BODY MODIFIED="2017-05-15 16:53:08 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="9">
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Virus</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Estimated annual proportion of cases</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>References</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Rhinoviruses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>30% to 50%; during autumn 80%. Once considered to be limited to the upper airway, now recognised as an important cause of lower respiratory infections </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Arruda-1997" TYPE="REFERENCE">Arruda 1997</LINK>; <LINK REF="REF-Gwaltney-1985" TYPE="REFERENCE">Gwaltney 1985</LINK>; <LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>; <LINK REF="REF-Lemanske-2005" TYPE="REFERENCE">Lemanske 2005</LINK>; <LINK REF="REF-Monto-1993" TYPE="REFERENCE">Monto 1993</LINK>; <LINK REF="REF-M_x00e4_kel_x00e4_-1998" TYPE="REFERENCE">Mäkelä 1998</LINK>; <LINK REF="REF-Regamey-2008" TYPE="REFERENCE">Regamey 2008</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Coronaviruses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>7% to 18% in adults with upper respiratory infections. Responsible for 2.1% of hospital admissions for acute respiratory tract infections in all age groups</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Larson-1980" TYPE="REFERENCE">Larson 1980</LINK>; <LINK REF="REF-Lau-2006" TYPE="REFERENCE">Lau 2006</LINK>; <LINK REF="REF-M_x00e4_kel_x00e4_-1998" TYPE="REFERENCE">Mäkelä 1998</LINK>; <LINK REF="REF-Nicholson-1997" TYPE="REFERENCE">Nicholson 1997</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Influenza viruses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>5% to 15%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Heikkinen-2003" TYPE="REFERENCE">Heikkinen 2003</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Respiratory syncytial virus (RSV)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>In low-income countries, 15% to 20%</P>
<P>In hospital the proportion of children aged between birth and 5 months with RSV acute lower respiratory tract infections ranged between 9% and 87%.</P>
<P>Among children up to at least 5 years of age reported with RSV, on average 39% (range 20% to 62%) were &lt; 6 months old; on average 24% of cases (range 14% to 38%) were children aged 6 to 11 months. An average of 63% of children were thus under 1 year of age. On average 20% (range 13% to 29%) of the children were between 1 and 2 years of age.</P>
<P>Respiratory syncytial virus accounts for approximately 10,000 deaths annually in people over the age of 65 years in the USA.</P>
<P>Respiratory syncytial virus in adults, 5% infection annually</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Berman-1991" TYPE="REFERENCE">Berman 1991</LINK>; <LINK REF="REF-Falsey-2005" TYPE="REFERENCE">Falsey 2005</LINK>; <LINK REF="REF-Thompson-2003" TYPE="REFERENCE">Thompson 2003</LINK>
</P>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Parainfluenza viruses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acute respiratory infections cause 3% to 18% of all admissions to paediatric hospitals; 9% to 30% of these patients depending on the time of year.</P>
<P>Parainfluenza viruses account for 17% of hospitalised illness-associated virus isolation.</P>
<P>In low-income countries 7% to 10%</P>
<P>This virus causes 50% to 74.2% of croup cases.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Berman-1991" TYPE="REFERENCE">Berman 1991</LINK>; <LINK REF="REF-Denny-1983" TYPE="REFERENCE">Denny 1983</LINK>; <LINK REF="REF-Henrickson-2003" TYPE="REFERENCE">Henrickson 2003</LINK>
</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Adenoviruses</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>In low-income countries can be summarised as 2% to 4% </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Berman-1991" TYPE="REFERENCE">Berman 1991</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Metapneumovirus</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>10% short epidemic</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Esper-2003" TYPE="REFERENCE">Esper 2003</LINK>; <LINK REF="REF-Kahn-2003" TYPE="REFERENCE">Kahn 2003</LINK>; <LINK REF="REF-Nissen-2002" TYPE="REFERENCE">Nissen 2002</LINK>; <LINK REF="REF-Risnes-2005" TYPE="REFERENCE">Risnes 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Unknown</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>20% to 30%</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="REF-Monto-1993" TYPE="REFERENCE">Monto 1993</LINK>; <LINK REF="REF-M_x00e4_kel_x00e4_-1998" TYPE="REFERENCE">Mäkelä 1998</LINK>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2017-05-18 07:26:14 +1000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2017-03-10 19:45:38 +1000" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2017-03-20 09:50:53 +1000" MODIFIED_BY="[Empty name]">
<P>#1 [mh "Common Cold"]<BR/>#2 "common cold*":ti,ab<BR/>#3 "coryza":ti,ab<BR/>#4 (acute near/5 ("upper respiratory infection*" or "upper respiratory tract infection*" or urti or uri)):ti,ab<BR/>#5 [mh "Picornaviridae Infections"]<BR/>#6 [mh Rhinovirus]<BR/>#7 "rhinovir*":ti,ab<BR/>#8 "hrv":ti,ab<BR/>#9 [mh "Paramyxoviridae Infections"]<BR/>#10 [mh "parainfluenza virus 1, human"] or [mh "parainfluenza virus 3, human"]<BR/>#11 [mh "parainfluenza virus 2, human"] or [mh "parainfluenza virus 4, human"]<BR/>#12 "parainfluenza*":ti,ab<BR/>#13 [mh coronavirus] or [mh "coronavirus 229e, human"] or [mh "coronavirus oc43, human"]<BR/>#14 [mh "Coronavirus Infections"]<BR/>#15 "coronavir*":ti,ab<BR/>#16 [mh adenoviridae] or [mh "adenoviruses, human"]<BR/>#17 [mh "Adenovirus Infections, Human"]<BR/>#18 "adenovir*":ti,ab<BR/>#19 [mh "respiratory syncytial viruses"] or [mh "respiratory syncytial virus, human"]<BR/>#20 [mh "Respiratory Syncytial Virus Infections"]<BR/>#21 ("respiratory syncytial virus*" or rsv):ti,ab<BR/>#22 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21<BR/>#23 [mh Vaccines]<BR/>#24 [mh Vaccination]<BR/>#25 (vaccin* or inocul* or immuni*):ti,ab<BR/>#26 #23 or #24 or #25<BR/>#27 #22 and #26<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2017-05-18 07:26:12 +1000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2015-01-22 14:55:26 +1000" MODIFIED_BY="[Empty name]">MEDLINE (Ovid) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-22 14:56:03 +1000" MODIFIED_BY="[Empty name]">
<P>1 Common Cold/<BR/>2 common cold*.tw.<BR/>3 coryza.tw.<BR/>4 (acute adj5 (upper respiratory infection* or upper respiratory tract infection* or urti or uri)).tw.<BR/>5 Picornaviridae Infections/<BR/>6 Rhinovirus/<BR/>7 rhinovir*.tw.<BR/>8 hrv.tw.<BR/>9 Paramyxoviridae Infections/<BR/>10 parainfluenza virus 1, human/ or parainfluenza virus 3, human/<BR/>11 parainfluenza virus 2, human/ or parainfluenza virus 4, human/<BR/>12 parainfluenza*.tw.<BR/>13 coronavirus/ or coronavirus 229e, human/ or coronavirus oc43, human/<BR/>14 Coronavirus Infections/<BR/>15 coronavir*.tw.<BR/>16 exp adenoviridae/ or adenoviruses, human/<BR/>17 Adenovirus Infections, Human/<BR/>18 adenovir*.tw.<BR/>19 respiratory syncytial viruses/ or respiratory syncytial virus, human/<BR/>20 Respiratory Syncytial Virus Infections/<BR/>21 (respiratory syncytial virus* or rsv).tw.<BR/>22 or/1-21<BR/>23 exp Vaccines/<BR/>24 exp Vaccination/<BR/>25 (vaccin* or inocul* or immuni*).tw.<BR/>26 or/23-25<BR/>27 22 and 26</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2017-05-18 07:26:08 +1000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2015-01-22 14:57:22 +1000" MODIFIED_BY="[Empty name]">Embase (Elsevier) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-22 14:58:56 +1000" MODIFIED_BY="[Empty name]">
<P>#27. #23 AND #26 <BR/>#26. #24 OR #25 <BR/>#25. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR 'cross-over':ab,ti OR volunteer*:ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti <BR/>#24. 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#23. #18 AND #22 <BR/>#22. #19 OR #20 OR #21 <BR/>#21. 'vaccination'/de <BR/>#20. vaccin*:ab,ti OR immuni*:ab,ti OR inocul*:ab,ti <BR/>#19. 'vaccine'/exp <BR/>#18. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 <BR/>#17. 'respiratory syncytial virus':ab,ti OR 'respiratory syncytial viruses':ab,ti OR rsv:ab,ti <BR/>#16. 'respiratory syncytial pneumovirus'/de OR 'respiratory syncytial virus infection'/de <BR/>#15. adenovir*:ab,ti <BR/>#14. 'adenovirus'/exp OR 'human adenovirus infection'/de <BR/>#13. coronavir*:ab,ti <BR/>#12. 'coronavirus'/de OR 'coronavirus infection'/de <BR/>#11. parainfluenza*:ab,ti <BR/>#10. 'parainfluenza virus 1'/de OR 'parainfluenza virus 2'/de OR 'parainfluenza virus 3'/de OR 'parainfluenza virus 4'/exp <BR/>#9. 'parainfluenza virus'/exp <BR/>#8. 'paramyxovirus infection'/de <BR/>#7. rhinovir*:ab,ti OR hrv:ab,ti <BR/>#6. 'rhinovirus infection'/de OR 'human rhinovirus'/de <BR/>#5. coryza:ab,ti <BR/>#4. 'acute upper respiratory infection':ab,ti OR 'acute upper respiratory infections':ab,ti OR 'acute upper respiratory tract infection':ab,ti OR 'acute upper respiratory tract infections':ab,ti OR (acute NEAR/5 (urti OR uri)):ab,ti <BR/>#3. 'viral upper respiratory tract infection'/de OR 'upper respiratory tract infection'/de <BR/>#2. 'common cold':ab,ti OR 'common colds':ab,ti <BR/>#1. 'common cold'/de OR 'common cold symptom'/de </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2017-05-18 07:26:05 +1000" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2011-03-30 15:06:16 +1000" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-03-30 15:20:27 +1000" MODIFIED_BY="[Empty name]">
<P>S34 S23 and S33 <BR/>S33 S24 or S25 or S26 or S27 or S28 or S29 or S30 or S31 or S32 <BR/>S32 (MH "Quantitative Studies") <BR/>S31 TI placebo* or AB placebo* <BR/>S30 (MH "Placebos") <BR/>S29 TI random* or AB random* <BR/>S28 TI (singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*) or AB (singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*) <BR/>S27 TI (singl* blind* or doubl* blind* or trebl* blind* or tripl* blind*) or AB (singl* blind* or doubl* blind* or trebl* blind* or tripl* blind*) <BR/>S26 TI clinic* w1 trial* or AB clinic* w1 trial* <BR/>S25 PT clinical trial <BR/>S24 (MH "Clinical Trials+") <BR/>S23 S18 and S22 <BR/>S22 S19 or S20 or S21 <BR/>S21 TI (vaccin* or immuni* or inocula*) or AB (vaccin* or immuni* or inocula*) <BR/>S20 (MH "Immunization") <BR/>S19 (MH "Vaccines+") <BR/>S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 <BR/>S17 TI (respiratory syncytial virus* or rsv ) or AB (respiratory syncytial virus* or rsv) <BR/>S16 (MH "Respiratory Syncytial Virus Infections") <BR/>S15 (MH "Respiratory Syncytial Viruses") <BR/>S14 TI adenovir* or AB adenovir* <BR/>S13 TI coronavir* or AB coronavir* <BR/>S12 (MH "Coronavirus+") <BR/>S11 (MH "Coronavirus Infections") <BR/>S10 TI parainfluenza* or AB parainfluenza* <BR/>S9 (MH "Paramyxovirus Infections") <BR/>S8 (MH "Paramyxoviruses") <BR/>S7 TI hrv or AB hrv <BR/>S6 TI rhinovir* or AB rhinovir* <BR/>S5 (MH "Picornavirus Infections") <BR/>S4 TI (upper respiratory tract infection* or upper respiratory infection*) or AB (upper respiratory tract infection* or upper respiratory infection*) <BR/>S3 TI coryza or AB coryza <BR/>S2 TI common cold* or AB common cold* <BR/>S1 (MH "Common Cold") <BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2017-05-18 07:25:57 +1000" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2017-05-15 13:58:20 +1000" MODIFIED_BY="[Empty name]">LILACS (BIREME) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-14 09:49:18 +1000" MODIFIED_BY="[Empty name]">
<P>(mh:"Common Cold" OR "common cold" OR "common colds" OR coryza OR "Resfriado Común" OR "Resfriado Comum" OR "Coriza Aguda" OR "Upper Respiratory Tract Infections" OR "upper respiratory tract infection" OR "Infecciones del Tracto Respiratorio Superior" OR "Infecciones de las Vías Respiratorias Superiores" OR "Infecções do Trato Respiratório Superior" OR "Infecções das Vias Respiratórias Superiores" OR "Infecções das Vias Aéreas Superiores" OR "Infecções do Sistema Respiratório Superior" OR mh:"Picornaviridae Infections" OR "Infecciones por Picornaviridae" OR "Infecções por Picornaviridae" OR "Picornavirus Infections" OR mh:rhinovirus OR rhinovir* OR "Virus de la Coriza" OR "Virus del Resfriado Común" OR "Vírus da Coriza" OR "Vírus do Resfriado Comum" OR hrv OR mh:"Paramyxoviridae Infections" OR parainfluenza* OR mh:"Parainfluenza Virus 1, Human" OR mh:"Parainfluenza Virus 2, Human" OR mh:"Parainfluenza Virus 3, Human" OR mh:"Parainfluenza Virus 4, Human" OR mh:"Coronavirus Infections" OR coronavir* OR mh:coronavirus OR mh:"Coronavirus 229E, Human" OR mh:"Coronavirus OC43, Human" OR mh:"Coronavirus NL63, Human" OR mh:adenoviridae OR mh:"Adenoviruses, Human" OR mh:"Adenovirus Infections, Human" OR adenovir* OR mh:"Respiratory Syncytial Viruses" OR "Virus Sincitiales Respiratorios" OR "Vírus Sinciciais Respiratórios" OR "Virus Sincitial Respiratorio" OR "Vírus Sincicial Respiratório" OR mh:"Respiratory Syncytial Virus, Human" OR "respiratory syncytial virus" OR "Virus Humano Respiratorio Sincitial" OR mh:"Respiratory Syncytial Virus Infections" OR "Infecciones por Virus Sincitial Respiratorio" OR "Infecções por Vírus Respiratório Sincicial" OR rsv) AND (mh:vaccines OR vaccin* OR vacunas OR vacinas OR mh:d20.215.894* OR mh:vaccination OR vacunación OR vacinação OR mh:"Mass Vaccination" OR mh:immunization OR inmunización OR imunização OR mh:e02.095.465.425.400* OR mh:e05.478.550* OR mh:n02.421.726.758.310* OR mh:n06.850.780.200.425* OR mh:n06.850.780.680.310* OR mh:sp2.026.182.113* OR mh:sp8.946.819.838* OR immuni* OR inmuni* OR imuni*) AND db:("LILACS") AND type_of_study:("clinical_trials")</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-03-12 10:31:33 +1000" MODIFIED_BY="Clare Dooley">

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 RCT included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;No additional studies included for this update&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full-text articles assessed for eligibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;221 potentially relevant publications screened&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;221 records after duplicates removed:&lt;/p&gt;&lt;p&gt;CENTRAL = 24&lt;br&gt;MEDLINE = 37&lt;br&gt;Embase = 148&lt;br&gt;CINAHL = 0&lt;br&gt;LILACS = 12&lt;br&gt;WHO ICTRP = 0&lt;/p&gt;" WIDTH="300"/>
<OUT TEXT="&lt;p&gt;218 publications excluded based on title/abstract&lt;/p&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;3 full-text articles excluded:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;not common cold (n = 2)&lt;/li&gt;&lt;li&gt;wrong intervention (n = 1)&lt;/li&gt;&lt;/ul&gt;" WIDTH="250"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_15772_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="15772"><ADDRESS><DEPARTMENT>Cochrane Ecuador. Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud Eugenio Espejo</DEPARTMENT><ORGANISATION>Universidad Tecnológica Equinoccial</ORGANISATION><ADDRESS_1>Avenida República de El Salvador 733 y Portugal Edificio Gabriela 3. Of. 403 Casilla Postal 17-17-525</ADDRESS_1><CITY>Quito</CITY><COUNTRY CODE="EC">Ecuador</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>